


Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis

Graphical Abstract



Authors

Huihui Fan, Huda I. Atiya, Yeh Wang, ..., Chelsea Chandler, Hui Shen, Lan G. Coffman

Correspondence

hui.shen@vai.org (H.S.),
coffmanl@upmc.edu (L.G.C.)

In Brief

Fan et al. demonstrate that ovarian cancer reprograms the epigenome of stromal cells, inducing a mesenchymal-to-epithelial transition (MET) to form carcinoma-associated mesenchymal stem cells (CA-MSCs). This MET, mediated by WT1 and EZH2, enables CA-MSC:cancer cell co-metastasis. EZH2 inhibition decreases CA-MSC-mediated metastasis, presenting a potential therapeutic opportunity in ovarian cancer.

Highlights

- Ovarian cancer induces an epigenomic MET in CA-MSCs
- CA-MSCs enhance metastasis through direct binding to cancer cells and co-metastasis
- MET in CA-MSCs is mediated by WT1 and EZH2
- CA-MSC MET is clinically significant and correlated with patient survival



Article

Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis

Huihui Fan,^{1,6} Huda I. Atiya,^{2,6} Yeh Wang,³ Thomas R. Pisanic,⁴ Tza-Huei Wang,⁴ Ie-Ming Shih,³ Kelly K. Foy,¹ Leonard Frisbie,² Ronald J. Buckanovich,^{2,5} Alison A. Chomiak,¹ Rochelle L. Tiedemann,¹ Scott B. Rothbart,¹ Chelsea Chandler,⁵ Hui Shen,^{1,7,*} and Lan G. Coffman^{2,5,7,8,*}

¹Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA

²Division of Hematology/Oncology, Department of Medicine, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA

³Department of Gynecology and Obstetrics, Department of Oncology, and Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

⁴Johns Hopkins Institute for NanoBiotechnology, Johns Hopkins University, Baltimore, MD, USA

⁵Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee Women's Research Institute, University of Pittsburgh, Pittsburgh, PA, USA

⁶These authors contributed equally

⁷Senior author

⁸Lead Contact

*Correspondence: hui.shen@vai.org (H.S.), coffmanl@upmc.edu (L.G.C.)

<https://doi.org/10.1016/j.celrep.2020.108473>

SUMMARY

A role for cancer cell epithelial-to-mesenchymal transition (EMT) in cancer is well established. Here, we show that, in addition to cancer cell EMT, ovarian cancer cell metastasis relies on an epigenomic mesenchymal-to-epithelial transition (MET) in host mesenchymal stem cells (MSCs). These reprogrammed MSCs, termed carcinoma-associated MSCs (CA-MSCs), acquire pro-tumorigenic functions and directly bind cancer cells to serve as a metastatic driver/chaperone. Cancer cells induce this epigenomic MET characterized by enhancer-enriched DNA hypermethylation, altered chromatin accessibility, and differential histone modifications. This phenomenon appears clinically relevant, as CA-MSC MET is highly correlated with patient survival. Mechanistically, mirroring MET observed in development, MET in CA-MSCs is mediated by WT1 and EZH2. Importantly, EZH2 inhibitors, which are clinically available, significantly inhibited CA-MSC-mediated metastasis in mouse models of ovarian cancer.

INTRODUCTION

Ovarian cancer, the deadliest gynecologic cancer, kills roughly 14,000 U.S. women yearly and 70% of all women with the disease. This high mortality is due to early, diffuse intra-abdominal metastatic spread. Ovarian cancer quickly colonizes the peritoneal cavity, building a complex tumor microenvironment (TME) that supports ovarian cancer survival, growth, and spread. This TME is a complex bionetwork of tumor, immune, and stromal cells (Tothill et al., 2008; Verhaak et al., 2013; Konecny et al., 2014; Karlan et al., 2014; Zhang et al., 2003).

Efforts to determine what drives the formation and function of the ovarian TME led to the identification of a critical stromal stem cell, the carcinoma-associated mesenchymal stem/stromal cell (CA-MSC) (McLean et al., 2011). CA-MSCs are benign stromal cells that meet all the criteria for mesenchymal stem/stromal cells (MSCs) as defined by the International Society for Cellular Therapy (ISCT) (Dominici et al., 2006). Karyotype analysis, high-resolution genotyping, and *in vivo* tumor initiation assays demonstrated that CA-MSCs have normal genomes

and lack tumor-related mutations and that isolated CA-MSCs lack malignant potential (McLean et al., 2011; Verardo et al., 2014). CA-MSCs are distinct from carcinoma-associated fibroblasts (CAFs) and other more terminally differentiated stromal cells with long-term proliferative capacity, lineage differentiation capacity, and a unique gene expression pattern (Augsten, 2014; Coffman et al., 2019). CA-MSCs enhance ovarian cancer growth and chemotherapy resistance, increase the cancer stem cell-like (CSC) pool, and dramatically alter the stromal TME, increasing tumor-associated fibrosis and inducing angiogenesis (Coffman et al., 2016b; Spaeth et al., 2009). CA-MSCs arise from resident tissue MSCs (Coffman et al., 2019). However, the mechanism driving the formation of a CA-MSC—and, thus, the ability to target these critical stromal cells—remains unknown. CA-MSCs have widespread, durable expression changes without gain of genomic mutations. These “mitotically and/or meiotically heritable changes in gene function that cannot be explained by changes in DNA sequence” are evocative of the exact definition of “epigenetics” by Riggs and colleagues (Martiniussen et al., 1996). Therefore, we hypothesized



that epigenetic reprogramming drives this conversion of a normal MSC into a CA-MSC. While cancer-related epigenetic changes are well documented in tumor cells, reciprocal changes in the stroma are less recognized (Sharma et al., 2010; Shen and Laird, 2013).

Here, we demonstrate that CA-MSCs, compared to normal MSCs, have a unique epigenetic landscape characterized by enhancer-enriched DNA hypermethylation, enrichment in repressive histone modifications, and altered chromatin accessibility. We demonstrate that normal MSCs undergo cancer-mediated epigenetic reprogramming to form a cancer-supportive CA-MSC. Unexpectedly, this reprogramming induces a partial mesenchymal-to-epithelial transition (MET), a process not previously recognized in cancer-associated stroma. This MET leads to increases in cell contact pathways and functional demonstration of increased binding of CA-MSCs to tumor cells. Direct binding of CA-MSCs to tumor cells increases ovarian cancer metastasis through a process of co-metastasis where CA-MSCs and tumor cells travel in complex to effectively colonize metastatic sites. We identify EZH2 and WT1 as potential mediators of CA-MSC epigenetic mesenchymal-to-epithelial reprogramming. Interrupting this reprogramming with an EZH2 inhibitor decreases the ability of ovarian cancer cells to metastasize in an orthotopic mouse model. Thus, in contrast to tumor cell epithelial-to-mesenchymal transition (EMT), stromal MET is critical to ovarian cancer metastasis. Importantly, in patients, this stromal MET phenotype can be altered and may present a novel therapeutic target.

RESULTS

CA-MSCs Have a Unique DNA Methylation Profile Compared to Normal Tissue MSCs

We hypothesized that CA-MSCs undergo epigenetic alterations, which drives their mitotically stable pro-tumorigenic phenotype. We used the Infinium MethylationEPIC (850K/EPIC/HM850) array to profile 13 CA-MSCs derived from high-grade serous ovarian cancer (HGSC) samples, 20 omental/adipose/fallopian tube (FT)-derived normal MSCs, and six patient tumor cell samples (Table S1). We performed data quality and sample quality controls, including purity determination and potential sample swaps. The promoter of MIR200C/141 is unmethylated in epithelial cells and methylated in mesenchymal cells (Vrba et al., 2010), and the methylation level (beta value) of MIR200C/141 directly corresponds to the fraction of non-epithelial cells (George et al., 2019; Cherniack et al., 2017). As expected, our MSCs had close to 100% methylation at the MIR200C/141 promoter site, consistent with a non-epithelial origin and high sample purity. In contrast, primary human tumor cell samples demonstrated lack of methylation at this locus (Figure 1A). One CA-MSC sample had low MIR200C/141 promoter methylation, consistent with tumor cell contamination, and this sample also clustered with sorted tumor cells (Figure S1) and was removed from all further analysis.

We also downloaded and reprocessed external DNA methylation data on normal cell types from prior publications (Patch et al., 2015; Klinkebiel et al., 2016), including normal FT epithelium (FTE) and ovary stroma, profiled on the earlier

generation Infinium HumanMethylation450 (450K) array. The intersect between the two platforms (450,161 CpGs) were used in joint analysis with these external normal controls. Uniform Manifold Approximation and Projection (UMAP) reveals clustering coinciding with sample type (Figure 1B), with a few exceptions. (1) One CA-MSC (CAMSC-OM08) grouped with the normal ovary stroma. After final pathology review, this sample was found to be derived from an ovarian carcinosarcoma, not HGSC. (2) One sample, CAMSC-OM01, grouped with CA-MSCs on the UMAP but clustered with the normal MSCs on the unsupervised hierarchical clustering (Figure 1C) and, overall, demonstrated an intermediate profile between normal MSCs and CA-MSCs. This sample was derived from tumor-adjacent omentum without clear malignant involvement and may represent a mixture of normal MSCs and CA-MSCs. (3) MSC-FT-BrcaR, derived from the right FT of a patient with a germline BRCA2 mutation undergoing risk reduction surgery, grouped with CA-MSCs. In contrast, MSCs derived from the left FT of the same patient grouped with normal MSCs as expected. The expression-based CA-MSC classifier score, which accurately distinguishes normal MSCs from CA-MSCs (Coffman et al., 2019) for the left FT MSCs, was 0.01 (consistent with a normal MSC) and for the right FT MSCs, it was 0.95 (approaching the CA-MSC threshold of 0.96), in line with the methylation grouping and indicating that certain stromal cells derived from a high-risk patient more closely align with cancer-associated stroma. As expected, flow-sorted tumor cells were the closest to the normal FTE, the presumed cell of origin for HGSC.

MSCs Derived from Patients with Complete Response to Chemotherapy Resemble Normal MSCs

Interestingly, MSCs derived from the omentum of patients treated with neoadjuvant chemotherapy who achieved a pathologic complete response in the omental tissue clustered with the normal MSCs ($n = 4$; MSC-OMneo1-4). Likewise, the expression classifier scores of these MSCs ranged from 0.01 to 0.15 (within the normal MSC range). Radiographic evidence of omental involvement prior to neoadjuvant chemotherapy was documented in all cases.

CA-MSCs Demonstrate Epigenetic Alteration Characterized by Hypermethylation at Distal Enhancers

The top 10,000 most variably methylated probes across all MSC samples demonstrated a clear delineation between CA-MSCs and normal MSCs (Figure 1C). CA-MSCs demonstrated distinct gains in DNA methylation versus normal MSCs (Figures 1D and 1E). Greater than 128,000 (32% out of ~401,000 filtered probes) differentially methylated cytosines (DMCs), mapping to 22,991 differentially methylated regions (DMRs), were identified based on a threshold of a false discovery rate (FDR) < 0.05. Such difference is more pronounced at distal rather than proximal sites (Figures 1F, S1B, and S1C), with distal regions three times more likely to acquire hypermethylation of >0.2 beta value difference compared to proximal regions. In other words, the observed DNA methylation changes preferentially occurred in enhancer regions.




Figure 1. CA-MSCs Have Unique DNA Methylation Profiles compared to Normal-Tissue MSCs

(A) DNA methylation at the *MIR141/MIR200C* promoter separates epithelial and mesenchymal samples. Rows indicate *MIR141/MIR200C* promoter region probes. Columns indicate cell type. Column-side color bars indicate sample group or tissue source. A blue-to-red gradient indicates a beta value of 0–1 (DNA methylation level of 0% to 100%) in all heatmaps. FT, fallopian tube; AD, adipose; OM, omentum; OV, ovary; OMMets, omentum metastasis.

(B) UMAP of DNA methylation. Each dot represents an individual sample. The two dimensions are the intersect set of 438,064 CpG loci present on both the EPIC and HM450 platforms.

(C) CA-MSCs have differential DNA methylation versus MSCs. Top variable CpG probes (rows) (N = 10,000; filter with standard deviation) of 13 CA-MSCs and 19 MSCs (columns). *MIR141/200C* promoter methylation—average of the three probes in (A)—indicates the mesenchymal component proportion per sample.

(D) Overall distribution (smoothed probability density distribution) per sample of DNA methylation beta values (x axis) for CA-MSCs (purple lines) and MSCs (green lines).

(E) Histogram of DNA methylation distribution (beta value) group differences between CA-MSCs and normal MSCs. Red indicates methylation difference > 0 (hypermethylation in CAMSCs); black indicates methylation difference < 0 (hypomethylation in CAMSCs).





(F) Distal regions show more frequent DNA methylation gain in CA-MSCs versus MSCs. Density and histogram plots for proximal and distal CpG probe set (vertical in order). Proximal probes, overlapping with transcript promoters (± 500 bp around the transcription start site; TSS). Distal probes, located near TFBSs (± 100 bp) but not within ± 2 bp from the TSS. Distal elements are almost three times more likely to acquire a DNA methylation gain greater than 0.2 in CA-MSCs.

(G) DNA methylation heatmap showing differential methylation cytosine sites (DMCs; N = 17,883) between CA-MSCs and MSCs.

CA-MSC DNA Methylation Profile Demonstrates Similarity to that of Epithelium

To understand the implications of such DNA methylation alterations, we examined sites with absolute beta value difference of greater than 0.2 in CA-MSCs versus normal MSCs (n = 36,606 in HM850 loci; n = 17,904 in HM850/HM450 intersect). Unexpectedly, at these differential methylation loci, CA-MSCs closely resembled FTE samples (Figure 1G), while normal MSCs were more similar to dermal fibroblasts. Similarly, CA-MSCs bore more resemblance to sorted HGSC cells, which are also epithelial in origin.

Intrigued by this result, we further examined all sites (instead of just CA-MSC versus MSC differential sites) in the HM850/HM450 intersect. It was clear that, although globally, CA-MSCs exhibit increased similarity to FTE samples (Figure S1D), they were distinct. We continued to investigate sites shared between, or unique to, MSCs, CA-MSCs, and FTE samples. CA-MSCs had a DNA methylation profile that combined MSC and FTE features, with a limited set of CA-MSC-specific hyper- and hypo-methylated sites, compared to shared sites with either MSC or FTE (Figure 2A). Therefore, CA-MSCs likely demonstrated an intermediate state between MSC and FTE. Importantly, CA-MSCs remain



(legend on next page)

distinct from cancer cells. CA-MSCs do not acquire tumor cell-related mutations, as demonstrated by our group and others previously (McLean et al., 2011; Verardo et al., 2014). We further confirmed the lack of p53 hotspot mutations in CA-MSCs by searching for the top 50 p53 mutations curated in the Catalogue of Somatic Mutations in Cancer database (COSMIC v90; GRCh37) (Tate et al., 2019) and verified that these hotspot mutations were not present in CA-MSC RNA-sequencing (RNA-seq) data (Coffman et al., 2019). CA-MSCs are also distinct from other epithelial and mesenchymal malignancies, including uterine carcinosarcoma and soft tissue sarcomas (Figure 2A).

Quantitative Methylation-Specific PCR (qMSP) Validates DMRs

To confirm the DNA methylation differences noted in the EPIC/HM850 array, we selected a panel of five top DMRs (CA-MSCs versus MSCs): two regions of hypermethylation (*SASH1* and *C13orf45*), and three regions of hypomethylation (*ELN*, *GATA6*, and *MARVELD2*). Average beta values for each CpG as determined by the microarray are plotted in Figure 2B. The qMSP assays were designed for each locus. qMSP was performed on an independent set of 6 additional normal MSCs and 9 CA-MSCs. Across the five loci tested, the pattern of methylation in CA-MSCs and normal MSCs was confirmed (Figure 2C).

CA-MSC-Associated DMRs Persist throughout Lineage Differentiation and Are Acquired during Cancer-Mediated Reprogramming of MSCs

To determine whether the observed differential DNA methylation is carried through differentiation and possibly impacts the phenotype of stromal fibroblast and adipocyte cells, we used the qMSP panel to characterize normal MSC and CA-MSC *in vitro* lineage-directed differentiation into fibroblasts or adipocytes (Figures S2A and S2B). These cells maintained their methylation status at these loci even after differentiation, indicating that CA-MSC reprogramming is independent of lineage-specific differentiation.

Given our previous work demonstrating that normal MSCs are induced by tumor cells to become CA-MSCs, we analyzed *in vitro* indirect cancer stimulation of normal MSCs (which yields a partial conversion to a CA-MSC) for the development of CA-MSC-specific DMRs with the qMSP assays discussed earlier. Three of the five loci tested demonstrated CA-MSC-like alterations, with acquisition of DNA methylation at *SASH1* and loss of methylation at *ELN* and *MARVELD2*. *C13orf45* and *GATA6* loci remained unchanged (Figure 2D). This finding suggests a partial conversion to a CA-MSC DNA methylation profile with *in vitro* cancer stimulation. This is consistent with a change in the CA-MSC classifier score from 0.1 in normal MSCs (consis-

tent with a normal phenotype) to 0.62 after indirect cancer stimulation (the threshold for CA-MSC is 0.96).

CA-MSCs Have Altered Chromatin Accessibility

We next analyzed the chromatin accessibility of CA-MSCs versus normal MSCs using the Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq). Clustering based on ATAC-seq peaks accurately separated normal MSCs from CA-MSCs (Figure 3A). DESeq2 identified 5,129 statistically differential peaks with an adjusted $p < 0.05$. Power was limited in this analysis, partly due to the small sample size after removing samples that failed quality control. However, even in the majority of sites that did not reach statistical significance, CA-MSCs in general demonstrated a decrease in accessibility compared to normal MSCs after normalizing for library size (Figure 3B), consistent with the observed widespread gain of DNA methylation in CA-MSCs. The differential peaks between CA-MSCs and MSCs were enriched for intergenic regions and depleted of CpG islands (Figures S3A and S3B). Overall, sites with reduced accessibility in CA-MSCs tended to have higher DNA methylation (Figure 3C).

DNA Methylation and Chromatin Accessibility Correspond to Transcriptomic Differences in CA-MSCs versus MSCs

We incorporated our DNA methylation and chromatin accessibility data (Figure 3D) with previously reported RNA-seq data (Coffman et al., 2019). In general, genes with gained peaks or lost peaks segregated based on gene expression. Genes exemplified by *WT1*, *LRRN4*, *KRT8*, *KRT18*, and *COL4A6* were significantly overexpressed in CA-MSCs and demonstrated hypomethylation and open ATAC peaks. In contrast, genes such as *COL15A1*, *EBF2*, *EDNRB*, and *COLEC12*, which have decreased expression in CA-MSCs, demonstrated hypermethylation and reduced ATAC peaks.

Gene Expression Pathway Analysis Demonstrates that CA-MSCs Have Altered Collagen Synthesis and Undergo a Partial MET

Pathway analysis of the most differentially expressed genes demonstrated an upregulation of multiple pathways associated with alterations in extracellular matrix and cell:cell and cell:matrix adhesion (Figures S3C and S3D). We validated alterations in collagen with increased expression of collagen IV (*COL4A6*) and decreased expression of collagen XV (*COL15A1*) in CA-MSCs versus normal MSCs (Figure S4A). We also demonstrated that CA-MSCs deposit significant extracellular collagen IV during *in vitro* culture, while normal MSCs deposit extracellular collagen XV (Figure S4B). Collagen IV and XV are basement membrane

Figure 2. Verification of Differential DNA Methylation Loci Demonstrating that Methylation Differences Are Acquired during CA-MSC Reprogramming

(A) DNA methylation heatmap of CpG probes hyper- or hypomethylated in CA-MSC, FTE, and MSC compared to normal ovarian stroma (ovary), fibroblast, HGSC, sarcoma (SARC), or uterine carcinosarcoma (UCS). A blue-to-red gradient indicates a beta value of 0–1.
(B) Top DMRs within five different genes chosen for quantitative methylation-specific PCR (qMSP) validation. The y axis indicates mean beta values; the x axis indicates probe location. Error bars represent SEM.
(C and D) qMSP of top DMRs validates differential methylation in 9 independent CA-MSCs and 6 MSCs. Cancer stimulation of normal MSCs *in vitro* induces a partial CA-MSC methylation pattern. Means and SEM of 3 independent samples are represented. The p values in (D) compare CS MSCs with normal or CA-MSCs.

proteins with apparently opposing roles in cancer; collagen IV is associated with invasion and metastasis, while collagen XV is found largely in normal tissues and decreases with cancer initiation (Clementz and Harris, 2013; Burnier et al., 2011). We also demonstrate that collagen IV is prevalent in ovarian cancer omental metastasis, while collagen XV is more abundant in normal omental tissue (Figure S4C).

We next focused on cell:cell and cell:matrix adhesion pathways, which were altered in CA-MSCs versus normal MSCs. CA-MSCs demonstrate increases in cell adhesion pathways, a largely epithelial feature, and downregulation of mesenchymal genes (Figures S3C and S3D). We took the top 25 epithelial and mesenchymal signature genes (E-genes and M-genes, respectively) from a previous study (Creighton et al., 2013), which were ranked based on the Pearson's correlations of gene expression with the EMT score calculated from the canonical EMT markers (Lee et al., 2006). CA-MSCs clearly exhibited higher expression of the E-genes and lower expression for the M-genes. A quantitative EMT score derived with a 16-gene signature from the same study also suggested that CA-MSCs, indeed, had a more "epithelial" signature, while normal MSCs had a more "mesenchymal" signature (Figure 4A). Gene set enrichment analysis (GSEA) showcased the downregulation of several EMT-related gene sets as well (Figure 4B). This observation coalesces with the DNA methylation results, which also suggest a partial MET in CA-MSCs.

To test whether CA-MSCs exhibit an increase in epithelial phenotypic characteristics such as increased cell adhesion capacity, we performed *in vitro* cell adhesion assays of tumor cells to normal MSCs or CA-MSCs. CA-MSCs had a 3-5 fold increase in tumor cell binding capacity after 30 min of co-incubation. This pattern is true, regardless of MSC or CA-MSC origin (FT or omentum), and is consistent across two ovarian cancer cell lines and one primary patient tumor cell line tested (Figures 4C and S5A). The increased tumor cell binding confirms the pathway analysis showing increased cell:cell adhesion in CA-MSCs.

CA-MSCs Are Found in Direct Contact with Ovarian Cancer Cells in Both Patient Tissue and Ascites

To understand the physiologic relevance of a partial MET resulting in enhanced adhesion of CA-MSCs to tumor cells, we analyzed tissue from metastatic ovarian cancer and isolated cellular complexes from the ascites of ovarian cancer patients. Metastatic tissue and cytopins of ascites cellular complexes

were analyzed with immunofluorescent confocal microscopy for Epcam (Pacific Blue)-positive tumor cells and CD90 (fluorescein isothiocyanate; FITC)/CD73 (red fluorescent protein [RFP])-positive CA-MSCs confirming physical interactions between CA-MSCs and tumor cells in both tissue and ascites (Figure 4D). To quantify the proportion of MSCs within malignant tissue and ascites compared to benign tissue, tissue or ascites cellular complexes were dissociated into single-cell suspensions. MSCs were identified via CD90, 73, 105+/CD45, 34, 14, 19-, and the percentage of MSCs within each tissue was quantified (Figure S3E). Overall, there was an increase in MSC populations within malignant tissue versus benign tissue. To further verify that CA-MSCs are distinct from tumor cells, lack of significant PAX8 expression in CA-MSCs was confirmed within ascites complexes with immunohistochemistry (Figure S5B). PAX8 protein levels were also assessed by western blot in ascites CA-MSCs, omental metastasis CA-MSCs, normal MSCs, and tumor cells demonstrating significantly less PAX8 in MSCs versus tumor cells and no difference in low PAX8 protein levels between CA-MSCs and normal MSCs (Figure S5C). All CA-MSCs were verified for appropriate surface marker expression and differentiation capacity (Figures S5D and S5E) to meet ISCT criteria for MSCs (Dominici et al., 2006).

CA-MSCs Enhance Ovarian Cancer Metastasis

We next assessed the role of CA-MSCs in ovarian cancer metastasis. We tested whether CA-MSCs support critical steps in ovarian cancer metastasis, including migration/invasion and survival under non-adherent conditions. CA-MSCs allowed to directly interact with tumor cells (CAOV3, OVSAGO, and OVCAR3) significantly enhanced tumor cell migration and invasion through a Matrigel-coated Transwell culture (Figure 4E). CA-MSCs also enhanced the ability of tumor cells to grow under non-adherent conditions as spheres (Figure 4F). Fluorescent microscopy of CA-MSCs (expressing mT) and tumor cells (expressing GFP) demonstrated that CA-MSCs and tumor cells remained in physical contact during migration/invasion and sphere formation, indicating co-migration and formation of heterocellular spheres (Figure 4Fi). Increasing the ratio of tumor cells to CA-MSCs from 1:1 to 10:1 under non-adherent conditions resulted in each tumor cell sphere containing at least one CA-MSC, even at low CA-MSC concentrations (Figure 4Fii). This indicates a preferential direct binding between these cell types. This also mirrors the ratio of tumor cells to CA-MSCs (~10:1) found in patient ascites cellular complexes (Figure S5F).


Figure 3. CA-MSCs Have Altered Chromatin Accessibility compared to Normal MSCs, which Correspond to DNA Methylation and RNA Expression Changes

(A) Principal-component analysis (PCA) on the merged peak regions from ATAC-seq.

(B) ATAC-seq heatmap per sample centered at the summits of all the merged peaks. The heatmap is based on a 10-bp-binned ATAC-seq signal, normalized against sequencing library size per sample. Signal profile is indicated on top of each heatmap. The y axis indicates signal strength at base resolution surrounding the peak summits.

(C) DNA methylation patterns around the summits for peak group gained, unchanged, and lost calculated from (B). Line plot centered on the summits of all the peaks within each group is plotted as the x axis. The y axis indicates the average of overlapping methylation difference.

(D) Integration of DNA methylation, gene expression, and ATAC-seq calls. Probe-level DNA methylation difference (CA-MSC – MSC) for promoter probes is plotted as the x axis. Expression fold changes (\log_2 -scaled) for the corresponding genes are plotted as the y axis. Dots/gene labels are colored based on gene-overlapping ATAC-seq peak orientations: red, open; blue, closed; and black, unaltered peaks in CA-MSCs versus MSCs. Genes with the largest expression alterations (50 gene fold change rank), and combined methylation and gene expression differences (absolute beta value difference > 0.5 and fold change > 2) are labeled with gene names.



(legend on next page)

Direct Tumor Cell:CA-MSC Interactions Mediate Enhancement of Ovarian Cancer Metastasis

To confirm that the enhancement of metastatic steps is mediated through direct CA-MSC:tumor cell interactions, we repeated the aforementioned experiments but prevented the direct interaction between CA-MSCs and tumor cells by encapsulating CA-MSCs in alginate or separating the cells by a permeable membrane (allowing paracrine signaling without direct contact). Luciferase-secreting CA-MSCs were used to verify the continued viability and effective protein secretion of encapsulated CA-MSCs (Figure S5G). Alginate encapsulated CA-MSCs failed to enhance tumor cell migration/invasion (Figure 4E). Similarly, CA-MSCs separated from tumor cells by a permeable membrane did not enhance tumor cell sphere formation (Figure 4F). Together, this indicates direct CA-MSC and tumor cell adhesion is critical to *in vitro* enhancement of metastasis.

We next assessed the impact of CA-MSCs in a murine model of metastasis. Ovarian cancer cells (OVCAR3) were implanted orthotopically in the ovarian bursa alone, with CA-MSCs or with alginate encapsulated CA-MSCs. Mice with tumor cells plus CA-MSCs demonstrated significant increases in metastasis and systemic illness, as measured by decreased weight over time, compared to mice with tumor cells alone or encapsulated CA-MSCs (Figure 4G). Mice with tumor cells with direct CA-MSC contact demonstrated significantly more intra-abdominal metastasis with co-localization of tumor cells and CA-MSCs at metastatic implants consistent with tumor cell:CA-MSC co-migration (Figures 4H and 4I). Mice with tumor cells alone or with encapsulated CA-MSCs demonstrated large localized ovarian tumors but did not develop ascites, distant abdominal metastasis, or lung or parenchymal liver metastasis (Figure 4H). CA-MSCs within the alginate capsule remained viable and were re-isolated at the time of necropsy. The ratio of tumor cells to CA-MSCs was calculated between primary tumor and metastatic tissues. A trend toward increased CA-MSCs within metastatic tissues was observed ($p = 0.06$, two-sided Wilcoxon signed-rank test; Figure 4I). Collectively, this indicates that CA-MSCs signif-

icantly enhance ovarian cancer metastasis via direct binding and co-metastasis with cancer cells.

WT1 Is a Driver of MET and Mediates CA-MSC Formation

One of the most significantly differentially regulated genes with increased RNA expression, decreased DNA methylation, and increased ATAC peak was *WT1* (Figures 3D and 5A). *WT1* expression is often found in cells going through METs or cells with mixed epithelial and mesenchymal properties, such as podocytes (Moore et al., 1998). *WT1* overexpression has been reported to induce MET and is a regulator of MET during development (Hohenstein and Hastie, 2006; Essafi et al., 2011). While known as a tumor marker, *WT1* is present in tumor-associated stroma (He et al., 2008; Hylander et al., 2006). Independent qRT-PCR validation of *WT1* expression demonstrated ~100-fold increased expression in CA-MSCs versus normal MSCs with corresponding increase in protein (Figures 5B and 5C). Further, cancer-stimulated (CS) reprogramming of CA-MSCs induced *WT1* expression (Figure 5C).

Interestingly, while Figure 3D showed a decrease in *WT1* promoter methylation associated with *WT1* overexpression, upon close examination of the entire *WT1* region (Figure 5A), we discovered that, at the promoter (differentially methylated region 1, green box), DNA methylation differences were carried by only a subset of the normal MSC samples. However, within the *WT1* gene body, there were two more differentially methylated regions, highlighted by cyan (region 2) and orange (region 3) boxes. These two regions were consistently methylated in normal MSCs and unmethylated in CA-MSCs. Each of these differentially methylated regions overlapped with a site with differential accessibility between CA-MSCs and MSCs as determined by ATAC-seq. These ATAC-seq differential peaks were statistically significant, even with the small sample size. In ENCODE histone modification data, both regions had enhancer marks in K562 cells, a malignant leukemia cell line, but not in normal human lung fibroblast (NHLF), a cell type that normal MSCs appear to resemble based on DNA methylation results. We further

Figure 4. CA-MSCs Undergo a Partial Mesenchymal-to-Epithelial Transition (MET), Leading to Increased Tumor Cell Binding and Increased Ovarian Cancer Metastasis

- (A) Heatmap of epithelial- and mesenchymal-signature genes indicates a partial MET in CA-MSCs. EMTness score is indicated as column annotation.
 (B) GSEA results support a potential MET in CA-MSCs. Genes are ranked based on CA-MSCs versus MSCs fold changes. Red stars indicate significance level. The y axis indicates normalized enrichment scores.
 (C) CA-MSCs demonstrate greater cancer cell adhesion versus normal MSCs. Quantification of adherent cancer cells to plastic, normal MSCs or CA-MSCs via fluorescent microscopy, cell counts per low power field (LPF).
 (D) Immunofluorescence of human HGSC metastatic omental tissue and cellular complexes isolated from malignant ascites. Confocal microscopy demonstrates tumor cells (TCs) in contact with CA-MSCs. Scale bars, 20 μ m.
 (E) CA-MSCs enhance the invasion of TCs through Matrigel-coated Transwells. TCs that invaded were counted per LPF. Alginate encapsulation (enc.) prevents enhanced invasion.
 (F) CA-MSCs enhance TC sphere growth via direct CA-MSC:TC interactions. Spheres containing GFP-TCs were quantified via fluorescent microscopy per LPF and compared to TCs alone and TCs allowed to directly or indirectly interact with CA-MSCs. (i) Representative picture of GFP-TCs and mT-CA-MSCs within heterocellular spheres. (ii) Quantification of spheres with at least one CA-MSC per TC sphere at 1:1 and 10:1 TC:CA-MSC ratios.
 (G) Orthotopic mouse model with increased metastasis when CA-MSCs are in contact with TCs. Mouse weight over time per group is plotted (*, ** indicate significant decrease in weight between time points, $p < 0.05$).
 (H) Quantification of organs with metastasis at necropsy demonstrating increased lung, liver, and intra-abdominal metastasis in the TC + CA-MSC group, which is decreased with enc. CA-MSC. distant abd mets, distant abdominal metastasis.
 (I) CA-MSCs co-localize with TCs at the primary and metastatic tumor and metastatic tumor sites have an increased proportion of CA-MSCs. Quantification of the TC-to-CA-MSC ratio in the TC + CA-MSC group.
 For all pooled data, means and SEM are represented.




Figure 5. *WT1* Is Associated with a Permissive Epigenetic State in CA-MSCs and Participates in the Formation of a CA-MSC

(A) Integrated view of epigenetic profiles for *WT1*. *WT1* transcripts are plotted under the chromosome ideogram. Arrows indicate transcript direction. Normalized read count (10-bp bins) for ATAC-seq is plotted under transcripts. Significantly gained peaks (Sig. ATAC-seq Peaks) in CA-MSCs are indicated by black boxes. Layered H3K4me1 (enhancer mark), H3K4me3 (promoter mark), and H3K27ac (active chromatin mark) ChIP-seq tracks from ENCODE for two cell types, K562 (purple) and NHLF (pink), are plotted below. H3K27ac ChIP-seq signal from four MSCs (This Study) is plotted. Each track represents one sample, with called peaks as shaded boxes under each H3K27ac track and colored according to peak strength. DNA methylation level for each CpG is plotted as a heatmap. Blue, DMR probe; green, CGI probe. Three regions of interest discussed in the text are highlighted with green (region 1), cyan (region 2), and orange (region 3) shaded boxes. The locations for these regions are indicated in the heatmap with the same color.

(B) In (i): western blot of *WT1* in MSCs and CA-MSCs. Actin is the loading control. In (ii): densitometry of western blot results (from a total of 10 independent MSCs and CA-MSCs).

(C) *WT1* fold expression change in normal MSCs versus CA-MSCs, cancer-stimulated (CS) MSCs, *WT1* OE MSCs, and *WT1* siRNA knockdown (KD) MSCs.

(D) Quantification of CA-MSC conversion in CS scrambled control MSCs, *WT1* OE MSCs alone, and CS *WT1* KD MSCs. The y axis indicates CA-MSC classifier score, CA-MSC threshold (0.96), and MSC threshold (0.3). Means and SEM of 3 independent experiments are represented. *Group versus scrambled control without CS; **Group versus scrambled control with CS.

performed H3K27ac ChIP-seq with additional normal MSCs and CA-MSCs and confirmed the presence of H3K27ac marks at these putative *WT1* enhancer elements discovered through differential DNA methylation in CA-MSCs. Hi-C data, DNase I-hypersensitive site (DHS) linkage data for k562 cells (Thurman et al., 2012), and regulatory interactions curated in GeneHancer database (Fishilevich et al., 2017) available through the 3D Genome Browser (Wang et al., 2018) all supported interactions between the two potential enhancers and the promoter region of gene *WT1* (Figure S6). These results suggest that hypomethy-

lation at these cryptic enhancers, associated with enhanced accessibility, likely turned this region, normally methylated in normal MSCs into an active enhancer, and greatly promotes *WT1* expression. Given the global trend of hypermethylation in CA-MSCs, this specific hypomethylation is even more likely to be a driver event.

To determine whether *WT1* is important in the formation of CA-MSCs, we created *WT1* overexpressing (OE) normal MSCs via lentiviral transduction. Compared to lenti-GFP control MSCs, *WT1* expression increased to levels approximating those of

CA-MSCs (Figure 5C). Analysis of the CA-MSC classifier score in *WT1* OE MSCs versus control MSCs demonstrated increase in the classifier score from 0.01 (a normal MSC score) to 0.99 (a CA-MSC score). This indicates that *WT1* overexpression drives the conversion of a normal MSC to a CA-MSC. We also performed small interfering RNA (siRNA)-mediated knockdown (KD) of *WT1* in normal MSCs. *WT1* KD MSCs underwent cancer stimulation via hypoxic direct co-culture with ovarian cancer cells, which we previously demonstrated was the most effective *in vitro* condition to convert a normal MSC to a CA-MSC. CS *WT1* KD MSCs, compared to CS control MSCs, demonstrated a 23% decrease in CA-MSC classifier score. We previously demonstrated a strong correlation between increasing classifier score and acquisition of tumor-promoting properties with full CA-MSC conversion occurring when classifier scores reach ≥ 0.96 . Importantly, no *WT1* KD MSCs reached the 0.96 threshold for full CA-MSC conversion (Figure 5D).

CA-MSC Expression Pattern Correlates with Altered EZH2 Binding Sites

DNA methylation alterations at enhancer regions can serve as a readout of overall activity of transcription factors, where hypermethylation often indicates an inactive transcription factor binding site (TFBS), and hypomethylation likely marks an active state (Yao et al., 2015). Enrichment analysis for annotated TFBSs identified EZH2 binding sites as the most significantly enriched category with hypermethylation in CA-MSCs (Figure 6A). Concomitantly, binding sites of SUZ12, a member of the polycomb repressive complex 2 (PRC2) along with EZH2, were also enriched.

Interestingly, EZH2/SUZ12 binding sites were also enriched in loci with hypomethylation (Figure 6A), indicating a likely redistribution of EZH2/SUZ12 targeting. Consistent with this observation, GSEA (Figure 6B) demonstrated an enrichment in 334 EZH2 targets as marked by 1,241 common H3K27me3 peaks from MSCs derived from four different cell types (Figure S7A) in both up- and downregulated genes in CA-MSCs versus normal MSCs.

CA-MSCs Are Enriched with PRC2-Related Histone Marks

Given the role of EZH2 in histone modifications at H3K27, we investigated global changes in histone modifications between CA-MSCs and normal MSCs. We performed mass spectrometry on the most common 80 histone modifications in CA-MSCs and MSCs. Out of the 80 modifications tested, six histone marks were differentially represented in CA-MSCs versus MSCs ($p < 0.1$): H3K27ac, H3K27me3, H1K26me1, H3K79me1, H3K27me2, and H4K16ac (Figure 6C). Differential histone modification was verified via western blot of independent MSCs and CA-MSCs (3 MSCs and 5 CAMSCs not used in the mass spectrometry screen). All histone differences were confirmed with the exception of H3K79me1 (Figures S7B and S7C). H3K27ac, H1K26me1, and H4K16ac are generally associated with transcriptional activation and were decreased in CA-MSCs. In contrast, H3K27me3 and H3K27me2 are associated with transcriptional repression and were increased in CA-MSCs. Three of the top six differential histone modifications are directly

related to the PRC2: H3K27me2, H3K27me3, and H3K27ac. This supports a role for EZH2 differential targeting in CA-MSC formation.

Further supporting a role for differential EZH2 targeting in CA-MSCs, during CA-MSC reprogramming, *EZH2* RNA expression is increased (Figure 6D). This induction occurs with paracrine tumor signaling during indirect tumor cell:MSC co-culture, conditions that, as we demonstrated earlier, induced DNA methylation changes in three of the five CA-MSC DMRs assessed in Figure 2. This indicates that *EZH2* induction happens early in CA-MSC reprogramming and is not dependent on the physical interaction between CA-MSC and tumor cells necessary for the enhancement of metastasis. This induction is also seen with *in vivo* cancer stimulation in a xenograft mouse model as previously described (Coffman et al., 2019). This implies a role for EZH2 during the initial stages of CA-MSC formation.

EZH2 Inhibition in Combination with *WT1* KD Blocks the Formation of a CA-MSC

Given our findings indicating altered EZH2 genomic targeting and known interaction between WT1 and EZH2/PRC2 targeting (Xu et al., 2011), we tested whether EZH2 and WT1 directly interact in CA-MSCs. Using co-immunoprecipitation (coIP) with an anti-EZH2 antibody in CA-MSCs, we demonstrated that WT1 is pulled down with EZH2 (Figure 6E). Further, using a proximity ligation assay (PLA), we demonstrated that WT1 and EZH2 do not interact in normal MSCs; however, during CS MSC reprogramming, WT1/EZH2 PLA signal is present in the nucleus, supporting a direct interaction during CA-MSC formation (Figure 6F). We then tested whether EZH2 inhibition, alone or in combination with *WT1* KD, would further decrease the development of a CA-MSC. To verify lack of toxicity, we performed viability studies with an EZH2 inhibitor, GSK126. At doses of 20 nM ($K_i = 0.59$ nM, half maximal inhibitory concentration [IC_{50}] = 9.9 nM), there was no significant decrease in cell viability of tumor cells or MSCs (Figure S8A). Next, *WT1* KD and scrambled control MSCs were treated with 20 nM GSK126 during cancer stimulation. GSK126 treatment of scrambled control MSCs led to a 38% decrease in CA-MSC classifier score. GSK126 treatment of *WT1* KD MSCs resulted in a 55% decrease in CA-MSC classifier score (Figure 6G). Importantly, none of the GSK126-treated MSCs reached the threshold of complete reprogramming, as defined as a classifier score ≥ 0.96 . Similar results were seen using a different EZH2 inhibitor, Tazemetostat (Figure S8B). Collectively, this demonstrates that WT1 and EZH2 jointly mediate the formation of a CA-MSC.

EZH2 Inhibition Limits Ovarian Cancer Metastasis

We next tested whether EZH2 inhibition impacted ovarian cancer metastasis. Using the ovarian bursal orthotopic mouse model discussed earlier, OVCAR3 tumor cells and CA-MSCs were injected into the right ovarian bursa. A subset of mice bearing luciferase-expressing OVCAR3 cells underwent serial In Vivo Imaging System (IVIS) imaging to monitor tumor growth. By 7 days, localized tumor engraftment was noted, and by 14 days, intraperitoneal metastasis developed (Figure 6H). After 14 days, 10 mice were treated with cisplatin alone and 10 mice were treated with cisplatin plus GSK126, starting after




Figure 6. EZH2 and WT1 Impact CA-MSC Reprogramming and Ovarian Cancer Metastasis

(A) Transcription factor binding site (TFBS) enrichment for distal DMCs hypermethylated (top) and hypomethylated (bottom) in CA-MSCs. The x axis indicates negative log₁₀-transformed FDRs.

(B) GSEA plot indicates enrichment of the Polycomb group (PcG) target genes on both ends of the ranked gene list (ordered by gene fold changes in CA-MSCs versus MSCs).

(C) Boxplots of top histone modifications differentially represented in CA-MSCs versus MSCs identified by mass spectrometry.

(D) EZH2 expression is increased during *in vitro* and *in vivo* cancer stimulation with ovarian cancer cells. Fold change compared to normal MSC.

(E) EZH2 directly interacts with WT1. The colP of EZH2 pulls down WT1.

(F) Proximity ligation assay (PLA) with EZH2 and WT1. Cancer stimulation yields nuclear signal indicating that WT1 and EZH2 are within 40 nm during CA-MSC reprogramming. Scale bars, 20 μm.

(G) WT1 knockdown (KD) with EZH2 inhibition partially blocks CA-MSC formation. Quantification of CA-MSC reprogramming in WT1 KD MSCs or scrambled control after cancer stimulation (CS) ± EZH2 inhibitor GSK126. The y axis indicates CA-MSC classifier score. CA-MSC threshold (0.96) and normal MSC threshold (0.3) depicted. *Comparison to scrambled control; **Comparison to CS scrambled control without GSK126.

(H) IVIS imaging of mice bearing luciferase-expressing cancer cells and CA-MSCs. Luciferase signal was detected within the abdomen in all mice by day 14, indicating development of metastasis.

(I) EZH2 inhibition with GSK126 significantly (p < 0.05) decreased metastatic disease at time of necropsy. Quantification of organs involved with gross metastatic disease at day 31.

(J) Quantification of viable CA-MSCs within the primary ovarian tumor at time of necropsy.

For pooled results, mean and SEM are indicated.

the first dose of cisplatin and continued as maintenance for 3 weeks. Five additional mice were left untreated as a control. IVIS imaging demonstrated decreased luciferase signal in the primary tumors of cisplatin-treated mice versus control and decreased metastatic signal in the cisplatin + GSK126-treated

mice. All mice were sacrificed on day 31 when the control group met endpoint criteria of 10% weight loss. At the time of necropsy, both the control and cisplatin-alone groups demonstrated 100% rates of gross lung, liver, and intra-peritoneal metastasis and 40%–75% rates of bowel obstruction. In




Figure 7. WT1 Stromal Expression Correlates with Ovarian Cancer Disease Status, and CA-MSC Normalization Is Associated with Improvement in Patient Outcomes

(A) WT1 immunohistochemistry of HGSC patient omentum after neoadjuvant therapy \pm residual carcinoma. Stromal nuclei are indicated by red arrows. Scale bar, 20 μ m.

(B) Quantification of WT1 stromal staining (H score) in tissue with residual carcinoma ($n = 5$) and without residual carcinoma ($n = 7$).

(C) Kaplan-Meier plot of progression-free survival (PFS) in women with normalized MSCs versus women with persistent CA-MSCs after neoadjuvant therapy.

contrast, mice with cisplatin and GSK126 treatment demonstrated 40% lung, 30% liver, and 50% intra-peritoneal metastasis, with no bowel obstructions, consistent with significant decrease in metastasis to all organs examined (Figure 6I). The primary tumor volume in the control group was 315 mm³ versus 97 mm³ in the cisplatin-only group and 80 mm³ in the cisplatin + GSK126 group, consistent with a significant reduction in primary tumor size with cisplatin treatment ($p < 0.001$) without a significant change in size with GSK126 addition ($p = 0.58$). This is consistent with our *in vitro* data demonstrating that EZH2 inhibition does not impact OVCAR3 cancer cell survival or proliferation and provides strong evidence that EZH2 inhibition targets CA-MSC-specific promotion of metastasis. We also assessed the presence of viable human CA-MSCs within the primary ovary tumor. Primary ovary tumors from the control and cisplatin-treated mice contained 9% and 7% viable CA-MSCs, respectively. In the cisplatin + GSK126 mice that developed metastasis, the primary tumor had 10.5% viable CA-MSCs compared to 1.2% viable CA-MSCs in the primary tumors of mice without metastasis ($p = 0.003$) (Figure 6J), demonstrating a strong correlation between viable CA-MSCs and the ability to form metastasis. This supports a potential therapeutic role for EZH2 inhibitors in treating and/or limiting CA-MSC-mediated ovarian cancer metastasis.

As ovarian cancer demonstrates both transcoelomic and hematogenous metastasis, we also used a previously described tail vein injection model of ovarian cancer, which yields robust intra-abdominal metastasis (Coffman et al., 2016a), to test the effect of EZH2 inhibition on hematogenous metastasis. Similarly, GSK126 decreased intra-abdominal metastasis by 50%–90%, adding additional evidence for a potential therapeutic role of

EZH2 inhibitors in limiting ovarian cancer metastasis (Figures S8C and S8D).

Ovarian Cancer Stroma Is Marked by WT1 Expression and Stromal WT1 Loss Is Associated with Treatment Response

We next explored whether the CA-MSC phenotype correlated with disease response in patient tissue. As CA-MSCs are marked by high *WT1* expression, we investigated whether *WT1* overexpression could serve as a marker of cancer-supportive stroma (associated with a CA-MSC phenotype) versus normalized stroma (associated with a normal MSC phenotype). Our findings indicated that CA-MSCs derived from tissue that achieved a complete pathologic response to neoadjuvant chemotherapy undergo phenotypic normalization and resemble normal MSCs with low *WT1* expression. We therefore investigated tissue obtained from interval debulking surgeries of patients treated with neoadjuvant platinum-based chemotherapy. We identified 5 patients with residual omental disease and 7 patients without residual omental disease (all HGSC histology, stage III/IV disease, with initial radiographic omental involvement). Sections were stained for WT1 and stromal WT1 levels were quantified by an H score (Figures 7A and 7B). WT1 was clearly present in stromal cells associated with residual disease (average H score = 154) but lost in tissue which achieved a pathologic complete response (average H score = 31; $p < 0.0001$). This indicates that the CA-MSC phenotype drives the tumor stromal microenvironment characterized by retained *WT1* overexpression and also indicates that normalization of the CA-MSC phenotype is possible and associated with treatment response (Figure 7).

Normalized Epigenetic Profile of MSCs Correlates with Improved Clinical Outcome

To further determine the clinical significance of the CA-MSC phenotype, we studied MSCs from a cohort of patients ($n = 29$) treated with neoadjuvant therapy. Patients were treated with platinum-based chemotherapy or with metformin as part of a phase-II clinical trial (ClinicalTrials.gov: NCT01579812) (Brown et al., 2020). All patients had stage III/IV disease, and all patients had viable tumor at the time of surgical debulking. MSCs were isolated from resected tissue at time of interval surgical debulking. MSCs

Normalized Epigenetic Profile of MSCs Correlates with Improved Clinical Outcome

To further determine the clinical significance of the CA-MSC phenotype, we studied MSCs from a cohort of patients ($n = 29$) treated with neoadjuvant therapy. Patients were treated with platinum-based chemotherapy or with metformin as part of a phase-II clinical trial (ClinicalTrials.gov: NCT01579812) (Brown et al., 2020). All patients had stage III/IV disease, and all patients had viable tumor at the time of surgical debulking. MSCs were isolated from resected tissue at time of interval surgical debulking. MSCs

from 15/29 (52%) patients retained the CA-MSC phenotype, while MSCs from 14/29 (48%) had a normal-like MSC phenotype (with a normal MSC DNA methylation profile and normal classifier score). Despite small numbers, the group with normalized MSCs had significantly improved progression-free survival (PFS). Mean PFS in the CA-MSC group was 266 days versus 870 days in the normalized MSC group (log rank, $p = 0.003$) (Figure 7C). Distribution of age, stage, and treatment type were not different ($p = 0.5$ for age, and $p = 0.6$ for stage and treatment type) between the two groups, and in a Cox proportional hazard model adjusting for treatment type, a normalized MSC phenotype remained as a significant protective factor ($p = 0.005$; hazard ratio [HR] = 0.23). Overall, this indicates that the CA-MSC phenotype is clinically important, is potentially reversible, and may present a novel therapeutic avenue in ovarian cancer.

DISCUSSION

Since described about a decade ago (Polyak and Weinberg, 2009; Klymkowsky and Savagner, 2009; Thiery et al., 2009; Yilmaz and Christofori, 2009; Barrallo-Gimeno and Nieto, 2005), partial transition to a mesenchymal phenotype in the epithelial compartment (i.e., EMT) in carcinomas has been well established as a hallmark of cancer with increased metastatic potential (Hanahan and Weinberg, 2011). Here, we describe alterations in the other direction—MET—in stromal progenitors of the TME that also contribute to cancer metastasis.

As stromal progenitor cells, CA-MSCs influence the formation of the TME. We demonstrate that CA-MSCs have a unique epigenetic landscape different from that of both tumor cells and normal MSCs, characterized by DNA hypermethylation, altered chromatin accessibility, and gain of repressive histone marks. The majority of differential DNA methylation occurs in enhancer regions. It has been previously shown that enhancers are the most dynamically utilized compartment (Sur and Taipale, 2016; Calo and Wysocka, 2013; Shlyueva et al., 2014) and closely relate to cellular identity. It has become increasingly clear that DNA methylation patterns are good markers for enhancer activity (Thomassin et al., 2001; Lister et al., 2009; Stadler et al., 2011; Yao et al., 2015; Blattler and Farnham, 2013). A recent publication (Corces et al., 2018) showed that DNA methylation tracks results from ATAC-seq for distal enhancers. As an example, DNA methylation alteration at the *WT1* loci helped to identify potential enhancers that are also marked by H3K27ac and ATAC-seq accessibility and/or curated as enhancers by GeneHancer (Fishilevich et al., 2017). Interestingly, at loci where CA-MSCs and MSCs differed, the DNA methylation profile of CA-MSCs resembles that of benign FTE and sorted carcinomas, while normal MSCs more closely resemble normal fibroblasts. While remaining mesenchymal in lineage, a partial MET appears to occur during CA-MSC formation, which facilitates direct binding to cancer cells, resulting in co-metastasis. This process of cancer cell and stromal cell co-metastasis is akin to the cancer “seed” traveling with its “soil” to enhance survival during metastasis and aid in distant colonization where the CA-MSC, as a stromal progenitor cell, may play a critical role in establishing the metastatic TME. This presents a new model of ovarian cancer metastasis where ovarian cancer cells reprogram normal MSCs into CA-MSCs, inducing a partial MET that en-

ables tumor cell:CA-MSC binding, co-metastasis, and establishment of new sites of disease with the supportive stromal TME already formed.

While stromal MET has not been previously identified in cancer, MSC MET has been reported in benign conditions. De-differentiation of mesenchymal cells such as fibroblasts into induced pluripotent stem cells (iPSCs) requires MET (Li et al., 2010; Shu and Pei, 2014). During embryogenesis, stem cells often transition from EMT to MET stages, and MET in stem cell reprogramming is associated with epigenetic changes, consistent with our findings (Wu et al., 2016). Also, normal epithelial or mesothelial progenitor cells that line the female reproductive tract may contribute to CA-MSC formation through acquiring mesenchymal features and increased differentiation capacity. We are actively investigating this possibility.

WT1, one of the most significantly upregulated genes in CA-MSCs, is an important mediator of MET during development and thought to be important in maintaining the potential to transition between EMT and MET (Miller-Hodges and Hohenstein, 2012). Interestingly, *WT1* impacts epigenetic regulation through directly binding the polycomb protein EZH2 and the DNA methyltransferases DNMT1 and DNMT3A (Xu et al., 2011; Szemes et al., 2013). Given the differential histone modifications (particularly related to PRC2 targets including H3K27me3) and DNA methylation changes in CA-MSCs, *WT1* may be an important mediator of these epigenetic modifications. Indeed, PLA and colP indicate that a *WT1*/EZH2 interaction in CA-MSCs and KD of *WT1* in combination with EZH2 inhibition during cancer stimulation blocked the formation of a CA-MSC. Pharmacologic inhibition of EZH2, while not impacting ovarian cancer cell proliferation or survival, significantly decreased CA-MSC-mediated ovarian cancer metastasis in an orthotopic mouse model. Importantly, while mice had documented intra-abdominal metastasis at the time of treatment initiation, only half of the mice had residual metastatic disease after cisplatin and EZH2 treatment. This indicates that EZH2 inhibition may play a role in limiting and/or treating already established ovarian cancer metastasis as is found at the time of clinical presentation in over 70% of ovarian cancer patients.

Dichotomous roles for MSCs in cancer growth have been reported with both tumor-promoting and tumor-suppressive functions (Klymenko and Nephew, 2018). Our work implies that the CA-MSC methylation profile drives the clinical impact of MSCs in ovarian cancer with a CA-MSC profile supporting cancer growth and a normal MSC profile restricting cancer growth. This is exemplified by a 20-month increase in PFS in women with normalized MSCs versus those with CA-MSCs. Ultimately, understanding the mechanistic steps leading to CA-MSC development and the ability to reverse, replace, or create MSCs resistant to reprogramming is essential to effective therapeutic targeting of the TME and represents a novel and powerful approach to ovarian cancer treatment.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE

- **RESOURCE AVAILABILITY**
 - Lead Contact
 - Materials Availability
 - Data and Code Availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
 - Human cancer cell lines
 - Human primary cell lines
 - Mice
- **METHOD DETAILS**
 - Tissue harvesting
 - DNA methylation array
 - Assay for Transposase Accessible Chromatin with sequencing (ATAC-seq)
 - Histone mass spectrometry
 - Quantitative real-time PCR
 - Immunoblotting
 - Quantitative Methylation Specific PCR (qMSP)
 - Locus-specific methylation analysis
 - Data Analysis
 - CA-MSC encapsulation
 - Sphere assays
 - Migration/Invasion assays
 - Adhesion assay
 - Cancer stimulation, cancer cell:MSC co-culture
 - CA-MSC classifier
 - Ascites complex isolation and flow cytometric analysis
 - Immunofluorescence staining
 - Orthotopic ovarian cancer mouse model
 - Tail vein injection model
 - Chromatin Immunoprecipitation
 - Transcriptome data re-processing
 - DNA methylation data processing and QC
 - ATAC sequencing (ATAC-seq) data processing
 - ChIP sequencing (ChIP-seq) data processing
 - Public available data resources
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
 - Identification of differential genes
 - Unsupervised DNA methylation analysis
 - Identification of CA-MSC/FTE/MS-C-specific probe sets
 - Identification of differential DNA methylation and functional enrichment analysis
 - Transcription factor binding site enrichment analysis
 - Identification of differential ATAC-seq peaks, functional enrichment, and PCA analysis
 - Key Resources Table references

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2020.108473>.

ACKNOWLEDGMENTS

We thank Marie Adams and the Van Andel Institute Genomics Core for DNA methylation microarray and ChIP-seq service and the VAI High Performance Computing Cluster supported by Zack Ramjan. L.G.C. is supported by NIH/NCI grant 7K08CA211362-02; a Tina's Wish Rising Star grant; a Mary Kay Foundation Cancer Research grant; and a DoD Ovarian Cancer, Omics

Consortium Development Award. H.S. is supported by NIH/NCI grant 1R37CA230748 and Ovarian Cancer Research Alliance's Liz Tilberis award (373933). S.B.R. is supported by NIH grant R35GM124736. A.A.C. is supported by NIH grant F32CA225043. R.L.T. is supported by the American Cancer Society–Michigan Cancer Research Fund (PF-16-245-01-DMC).

AUTHOR CONTRIBUTIONS

Conceptualization, L.G.C. and H.S.; Methodology, L.G.C., H.S., H.F., L.F., C.C., T.R.P., Y.W., R.L.T., A.A.C., and S.B.R.; Formal Analysis, L.G.C., H.S., and H.F.; Investigation, L.G.C., L.F., C.C., H.F., H.I.A., R.B., R.L.T., A.A.C., and S.B.R.; Writing – Original Draft, L.G.C. and H.S.; Writing – Review & Editing, L.G.C., H.S., H.F., T.R.P., H.I.A., and R.B.; Funding Acquisition, L.G.C., H.S., I.-M.S., and T.-H.W.; Resources, L.G.C., H.S., T.R.P., I.-M.S., T.-H.W., and S.B.R.; Supervision, L.G.C., H.S., I.-M.S., T.-H.W., and S.B.R.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: October 2, 2019

Revised: August 26, 2020

Accepted: November 11, 2020

Published: December 8, 2020

REFERENCES

- Alcoser, S.Y., Kimmel, D.J., Borgel, S.D., Carter, J.P., Dougherty, K.M., and Hollingshead, M.G. (2011). Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts. *BMC Biotechnol.* *11*, 124.
- Augsten, M. (2014). Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. *Front. Oncol.* *4*, 62.
- Barrallo-Gimeno, A., and Nieto, M.A. (2005). The Snail genes as inducers of cell movement and survival: implications in development and cancer. *Development* *132*, 3151–3161.
- Blattler, A., and Farnham, P.J. (2013). Cross-talk between site-specific transcription factors and DNA methylation states. *J. Biol. Chem.* *288*, 34287–34294.
- Brown, J.R., Chan, D.K., Shank, J.J., Griffith, K.A., Fan, H., Szulawski, R., Yang, K., Reynolds, R.K., Johnston, C., McLean, K., et al. (2020). Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. *JCI Insight* *5*, 133247.
- Burnier, J.V., Wang, N., Michel, R.P., Hassanain, M., Li, S., Lu, Y., Metrakos, P., Anteck, E., Burnier, M.N., Ponton, A., et al. (2011). Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. *Oncogene* *30*, 3766–3783.
- Calo, E., and Wysocka, J. (2013). Modification of enhancer chromatin: what, how, and why? *Mol. Cell* *49*, 825–837.
- Cherniack, A.D., Shen, H., Walter, V., Stewart, C., Murray, B.A., Bowlby, R., Hu, X., Ling, S., Soslow, R.A., Broaddus, R.R., et al.; Cancer Genome Atlas Research Network (2017). Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell* *31*, 411–423.
- Clementz, A.G., and Harris, A. (2013). Collagen XV: exploring its structure and role within the tumor microenvironment. *Mol. Cancer Res.* *11*, 1481–1486.
- Coffman, L.G., Burgos-Ojeda, D., Wu, R., Cho, K., Bai, S., and Buckanovich, R.J. (2016a). New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. *Transl. Res.* *175*, 92–102.e2.
- Coffman, L.G., Choi, Y.J., McLean, K., Allen, B.L., di Magliano, M.P., and Buckanovich, R.J. (2016b). Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. *Oncotarget* *7*, 6916–6932.

- Coffman, L.G., Pearson, A.T., Frisbie, L.G., Freeman, Z., Christie, E., Bowtell, D.D., and Buckanovich, R.J. (2019). Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma. *Stem Cells* 37, 257–269.
- Corces, M.R., Granja, J.M., Shams, S., Louie, B.H., Seoane, J.A., Zhou, W., Silva, T.C., Groeneveld, C., Wong, C.K., Cho, S.W., et al.; Cancer Genome Atlas Analysis Network (2018). The chromatin accessibility landscape of primary human cancers. *Science* 362, eaav1398.
- Creighton, C.J., Gibbons, D.L., and Kurie, J.M. (2013). The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. *Cancer Manag. Res.* 5, 187–195.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21.
- Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D.J., and Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 8, 315–317.
- Essafi, A., Webb, A., Berry, R.L., Slight, J., Burn, S.F., Spraggon, L., Velecela, V., Martinez-Estrada, O.M., Wiltshire, J.H., Roberts, S.G., et al. (2011). A wt1-controlled chromatin switching mechanism underpins tissue-specific wnt4 activation and repression. *Dev. Cell* 21, 559–574.
- Fishilevich, S., Nudel, R., Rappaport, N., Hadar, R., Plaschkes, I., Iny Stein, T., Rosen, N., Kohn, A., Twik, M., Safran, M., et al. (2017). GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. *Database (Oxford)* 2017, bax028.
- George, J.W., Fan, H., Johnson, B., Carpenter, T.J., Foy, K.K., Chatterjee, A., Patterson, A.L., Koeman, J., Adams, M., Madaj, Z.B., et al. (2019). Integrated epigenome, exome and transcriptome analyses reveal molecular subtypes and homeotic transformation in uterine fibroids. *Cell Rep* 29, 4069–4085.e6.
- Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144, 646–674.
- He, H., Luthringer, D.J., Hui, P., Lau, S.K., Weiss, L.M., and Chu, P.G. (2008). Expression of CD56 and WT1 in ovarian stroma and ovarian stromal tumors. *Am. J. Surg. Pathol.* 32, 884–890.
- Hohenstein, P., and Hastie, N.D. (2006). The many facets of the Wilms' tumour gene, WT1. *Hum. Mol. Genet.* 15, R196–R201.
- Hylander, B., Repasky, E., Shrikant, P., Intengan, M., Beck, A., Driscoll, D., Singhal, P., Lele, S., and Odunsi, K. (2006). Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. *Gynecol. Oncol.* 101, 12–17.
- Karlan, B.Y., Dering, J., Walsh, C., Orsulic, S., Lester, J., Anderson, L.A., Ginther, C.L., Fejzo, M., and Slamon, D. (2014). POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. *Gynecol. Oncol.* 132, 334–342.
- Karolchik, D., Baertsch, R., Diekhans, M., Furey, T.S., Hinrichs, A., Lu, Y.T., Roskin, K.M., Schwartz, M., Sugnet, C.W., Thomas, D.J., et al.; University of California Santa Cruz (2003). The UCSC Genome Browser Database. *Nucleic Acids Res.* 31, 51–54.
- Klinkebiel, D., Zhang, W., Akers, S.N., Odunsi, K., and Karpf, A.R. (2016). DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. *Mol. Cancer Res.* 14, 787–794.
- Klymenko, Y., and Nephew, K.P. (2018). Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled. *Cancers (Basel)* 10, 295.
- Klymkowsky, M.W., and Savagner, P. (2009). Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. *Am. J. Pathol.* 174, 1588–1593.
- Koh, C.M. (2013). Preparation of cells for microscopy using cytospin. *Methods Enzymol.* 533, 235–240.
- Konecny, G.E., Wang, C., Hamidi, H., Winterhoff, B., Kallil, K.R., Dering, J., Ginther, C., Chen, H.W., Dowdy, S., Cliby, W., et al. (2014). Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. *J. Natl. Cancer Inst.* 106, dju249.
- Lee, J.M., Dedhar, S., Kalluri, R., and Thompson, E.W. (2006). The epithelial-mesenchymal transition: new insights in signaling, development, and disease. *J. Cell Biol.* 172, 973–981.
- Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv*, arXiv:1303.3997. <https://arxiv.org/abs/1303.3997>.
- Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* 12, 323.
- Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25, 1754–1760.
- Li, R., Liang, J., Ni, S., Zhou, T., Qing, X., Li, H., He, W., Chen, J., Li, F., Zhuang, Q., et al. (2010). A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. *Cell Stem Cell* 7, 51–63.
- Lister, R., Pelizzola, M., Dowen, R.H., Hawkins, R.D., Hon, G., Tonti-Filippini, J., Nery, J.R., Lee, L., Ye, Z., Ngo, Q.M., et al. (2009). Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* 462, 315–322.
- Lo, Y.M., Wong, I.H., Zhang, J., Tein, M.S., Ng, M.H., and Hjelm, N.M. (1999). Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. *Cancer Res.* 59, 3899–3903.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550.
- Lun, A.T., and Smyth, G.K. (2016). csaw: a Bioconductor package for differential binding analysis of ChIP-seq data using sliding windows. *Nucleic Acids Res.* 44, e45.
- Martienssen, R.A., Riggs, A.D., and Russo, V.E.A. (1996). *Epigenetic Mechanisms of Gene Regulation* (Cold Spring Harbor Laboratory Press).
- McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K.R., and Buckanovich, R.J. (2011). Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. *J. Clin. Invest.* 121, 3206–3219.
- Miller-Hodges, E., and Hohenstein, P. (2012). WT1 in disease: shifting the epithelial-mesenchymal balance. *J. Pathol.* 226, 229–240.
- Moore, A.W., Schedl, A., McInnes, L., Doyle, M., Hecksher-Sorensen, J., and Hastie, N.D. (1998). YAC transgenic analysis reveals Wilms' tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb. *Mech. Dev.* 79, 169–184.
- Patch, A.M., Christie, E.L., Etemadmoghadam, D., Garsed, D.W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P.J., et al.; Australian Ovarian Cancer Study Group (2015). Whole-genome characterization of chemoresistant ovarian cancer. *Nature* 521, 489–494.
- Peters, T.J., Buckley, M.J., Statham, A.L., Pidsley, R., Samaras, K., Lord, R.V., Clark, S.J., and Molloy, P.L. (2015). De novo identification of differentially methylated regions in the human genome. *Epigenetics Chromatin* 8, 6.
- Polyak, K., and Weinberg, R.A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat. Rev. Cancer* 9, 265–273.
- Ramírez, F., Ryan, D.P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A.S., Heyne, S., Dündar, F., and Manke, T. (2016). deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res.* 44 (W1), W160–W165.
- Ripley, B.D. (2001). R studio v3.4.1 (R Foundation for Statistical Computing).
- Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 43, e47.
- Schmitt, A., Rödel, P., Anamur, C., Seeliger, C., Imhoff, A.B., Herbst, E., Vogt, S., van Griensven, M., Winter, G., and Engert, J. (2015). Calcium alginate gels as stem cell matrix-making paracrine stem cell activity available for enhanced healing after surgery. *PLoS ONE* 10, e0118937.

- Sharma, S., Kelly, T.K., and Jones, P.A. (2010). Epigenetics in cancer. *Carcinogenesis* *31*, 27–36.
- Shen, H., and Laird, P.W. (2013). Interplay between the cancer genome and epigenome. *Cell* *153*, 38–55.
- Shlyueva, D., Stampfel, G., and Stark, A. (2014). Transcriptional enhancers: from properties to genome-wide predictions. *Nat. Rev. Genet.* *15*, 272–286.
- Shu, X., and Pei, D. (2014). The function and regulation of mesenchymal-to-epithelial transition in somatic cell reprogramming. *Curr. Opin. Genet. Dev.* *28*, 32–37.
- Spaeth, E.L., Dembinski, J.L., Sasser, A.K., Watson, K., Klopp, A., Hall, B., Andreeff, M., and Marini, F. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. *PLoS ONE* *4*, e4992.
- Stadler, M.B., Murr, R., Burger, L., Ivanek, R., Lienert, F., Schöler, A., van Nimwegen, E., Wirbelauer, C., Oakeley, E.J., Gaidatzis, D., et al. (2011). DNA-binding factors shape the mouse methylome at distal regulatory regions. *Nature* *480*, 490–495.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* *102*, 15545–15550.
- Sur, I., and Taipale, J. (2016). The role of enhancers in cancer. *Nat. Rev. Cancer* *16*, 483–493.
- Szemes, M., Dallosso, A.R., Melegh, Z., Curry, T., Li, Y., Rivers, C., Uney, J., Mägdefrau, A.S., Schwiderski, K., Park, J.H., et al. (2013). Control of epigenetic states by WT1 via regulation of de novo DNA methyltransferase 3A. *Hum. Mol. Genet.* *22*, 74–83.
- Tate, J.G., Bamford, S., Jubb, H.C., Sondka, Z., Beare, D.M., Bindal, N., Boutselakis, H., Cole, C.G., Creatore, C., Dawson, E., et al. (2019). COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids Res.* *47* (D1), D941–D947.
- Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-mesenchymal transitions in development and disease. *Cell* *139*, 871–890.
- Thomassin, H., Flavin, M., Espinás, M.L., and Grange, T. (2001). Glucocorticoid-induced DNA demethylation and gene memory during development. *EMBO J.* *20*, 1974–1983.
- Thurman, R.E., Rynes, E., Humbert, R., Vierstra, J., Maurano, M.T., Haugen, E., Sheffield, N.C., Stergachis, A.B., Wang, H., Vernot, B., et al. (2012). The accessible chromatin landscape of the human genome. *Nature* *489*, 75–82.
- Tothill, R.W., Tinker, A.V., George, J., Brown, R., Fox, S.B., Lade, S., Johnson, D.S., Trivett, M.K., Etemadmoghadam, D., Locandro, B., et al.; Australian Ovarian Cancer Study Group (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. *Clin. Cancer Res.* *14*, 5198–5208.
- Verardo, R., Piazza, S., Klaric, E., Ciani, Y., Bussadori, G., Marzinotto, S., Marzuzzi, L., Cesselli, D., Beltrami, A.P., Mano, M., et al.; Fantom Consortium (2014). Specific mesothelial signature marks the heterogeneity of mesenchymal stem cells from high-grade serous ovarian cancer. *Stem Cells* *32*, 2998–3011.
- Verhaak, R.G., Tamayo, P., Yang, J.Y., Hubbard, D., Zhang, H., Creighton, C.J., Fereday, S., Lawrence, M., Carter, S.L., Mermel, C.H., et al.; Cancer Genome Atlas Research Network (2013). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. *J. Clin. Invest.* *123*, 517–525.
- Vrba, L., Jensen, T.J., Garbe, J.C., Heimark, R.L., Cress, A.E., Dickinson, S., Stampfer, M.R., and Futscher, B.W. (2010). Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. *PLoS ONE* *5*, e8697.
- Wang, Y., Song, F., Zhang, B., Zhang, L., Xu, J., Kuang, D., Li, D., Choudhary, M.N.K., Li, Y., Hu, M., et al. (2018). The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions. *Genome Biol.* *19*, 151.
- Weisenberger, D.J., Campan, M., Long, T.I., Kim, M., Woods, C., Fiala, E., Ehrlich, M., and Laird, P.W. (2005). Analysis of repetitive element DNA methylation by MethyLight. *Nucleic Acids Res.* *33*, 6823–6836.
- Wu, J., Ocampo, A., and Belmonte, J.C.I. (2016). Cellular Metabolism and Induced Pluripotency. *Cell* *166*, 1371–1385.
- Xu, B., Zeng, D.Q., Wu, Y., Zheng, R., Gu, L., Lin, X., Hua, X., and Jin, G.H. (2011). Tumor suppressor menin represses paired box gene 2 expression via Wilms tumor suppressor protein-polycomb group complex. *J. Biol. Chem.* *286*, 13937–13944.
- Yao, L., Shen, H., Laird, P.W., Farnham, P.J., and Berman, B.P. (2015). Inferring regulatory element landscapes and transcription factor networks from cancer methylomes. *Genome Biol.* *16*, 105.
- Yilmaz, M., and Christofori, G. (2009). EMT, the cytoskeleton, and cancer cell invasion. *Cancer Metastasis Rev.* *28*, 15–33.
- Yu, G., Wang, L.G., Han, Y., and He, Q.Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* *16*, 284–287.
- Yue, F. (2018). 4C Browser. <http://promoter.bx.psu.edu/hi-c/virtual4c.php>.
- Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M.N., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N. Engl. J. Med.* *348*, 203–213.
- Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* *9*, R137.
- Zhou, W., Laird, P.W., and Shen, H. (2017). Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res.* *45*, e22.
- Zhou, W., Triche, T.J., Jr., Laird, P.W., and Shen, H. (2018). SeSAMe: reducing artifactual detection of DNA methylation by Infinium BeadChips in genomic deletions. *Nucleic Acids Res.* *46*, e123.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
CD105	BD PharMingen	Cat# 561443
CD90	BD PharMingen	Cat# 555596
CD73	BD PharMingen	Cat# 560847
CD45	BD PharMingen	Cat# 340664
CD34	BD PharMingen	Cat# 555824
FSP	Novus	Cat# NB100-1845; RRID:AB_10000870
Alpha smooth muscle actin	Abcam	Cat# AB5694; RRID:AB_2223021
Anti-H3K27me3	Active Motif	Cat# 39155; RRID:AB_2561020
anti-PAX8	Abcam	Cat# AB13611; RRID:AB_300497
anti-WT1	R&D System	Cat# IC57291V
anti-H3K27me2	Active Motif	Cat# 39535; RRID:AB_2793246
anti-H4K16ac	Active Motif	Cat# 61529; RRID:AB_2793671
anti-H3K27ac	Active Motif	Cat# 39133; RRID:AB_2561016
anti-H3	Abcam	Cat# AB192985; RRID:AB_2650559
anti-EZH2	Abcam	Cat# AB191080; RRID:AB_304045
anti-H4	Abcam	Cat# AB177840; RRID:AB_2650469
anti-EpCAM	Novus	Cat# NB600-1182AF; RRID:AB_10008035
COL 4	Abcam	Cat# AB6586; RRID:AB_305584
COL 15	Abcam	Cat# AB150463; RRID:AB_879744
Bacterial and Virus Strains		
LV-EF1 α -tdTOMATO	SignaGen Laboratories	Cat# SL100289
LV-Synapsin-GFP	SignaGen Laboratories	Cat# SL100271
Chemicals, Peptides, and Recombinant Proteins		
SYBR green master-Mix	Applied Biosystem	Cat# 4472908
RIPA buffer	Pierce, Rockford, IL	Cat# 89900
NuPAGE SDS gel	Invitrogen, Grand Island, NY	Cat# NW04122
PVDF membrane	GE Healthcare Life Science	Cat# 10600001
Alginate	Sigma	Cat# 71238
Matrigel	Corning	Cat# 354230
Red blood cells lysis buffer	ThermoFisher Scientific	Cat# 11814389001
Cisplatin	Fresenius-Kabi	Cat# 4015721
GSK126	Selleckchem	Cat# S7061
Dynabeads Protein G magnetic beads	Invitrogen, Grand Island, NY	Cat# 10004D
Herring Sperm DNA	Sigma	Cat# D7290
KAPA Pure Beads	KAPA Biosystems	Cat# KK8000
Critical Commercial Assays		
Mycoplasma Kit	ABm	Cat# G238
DNA isolation kit	QIAGEN, Hilden, Germany	Cat# 69504
RNeasy Mini Kit	QIAGEN, Hilden, Germany	Cat# 28106
SuperScript III First Strand Synthesis System	Invitrogen, Grand Island, NY	Cat# 18080-051
Bradford Protein Assay Kit	ThermoFisher Scientific	Cat# 23227
Qubit dsDNA High Sensitivity Assay kit	ThermoFisher Scientific	Cat# Q32851
KAPA HyperPrep Kit	Kappa Biosystems	Cat# 07962347001

(Continued on next page)

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Continued		
Deposited Data		
DNA methylation (EPIC array data)	This paper	GSE138072
ATAC sequencing	This paper	SRP289005
ChIP sequencing	This paper	SRP289183
Mendeley dataset	This paper	https://dx.doi.org/10.17632/bdywxt6cvv.1
Experimental Models: Cell Lines		
OVCAR3	ATCC	Cat# HTB-161; RRID:CVCL_0465
CAOV3	ATCC	Cat# HTB-75; RRID:CVCL_0201
Experimental Models: Organisms/Strains		
NSG mice	The Jackson Laboratory	Cat# 005557; RRID:IMSR_JAX:005557
Software and Algorithms		
PEPATAC	Corces et al., 2018	http://pepatac.databio.org/en/latest/
BWA mem algorithm	Li, 2013	https://github.com/lh3/bwa
MACS2 v 2.2.7.1	Zhang et al., 2008	https://github.com/macs3-project/MACS
R studio v3.4.1 and v3.4.4	Ripley, 2001	https://www.r-project.org
STAR v2.7	Dobin et al., 2013	https://github.com/alexdobin/STAR/releases
RSEM v1.3.1	Li et al., 2010	https://deweylab.github.io/RSEM/
deepTools v2.0	Ramírez et al., 2016	https://deeptools.readthedocs.io/en/develop/
Other		
Molecular Signatures Database (MSigDB)	Subramanian et al., 2005	https://www.gsea-msigdb.org/gsea/msigdb/index.jsp
UCSC genome browser	Karolchik et al., 2003	http://genome.ucsc.edu
EPIC array probe annotations	Zhou et al., 2017	https://zwdzwd.github.io/InfiniumAnnotation
4C Browser	Yue, 2018	http://promoter.bx.psu.edu/hi-c/virtual4c.php
Genomic Data Commons (GDC) Data Portal	National Institutes of Health National Cancer Institute	https://portal.gdc.cancer.gov
Pure, uncultured fallopian tube epithelium samples	GEO database	GSE81224; GSE65820
Gapped H3K27me3 chromatin peak files	NIH Roadmap Epigenomics projects	http://www.roadmapepigenomics.org/data/
Raw mRNA sequencing data (FASTQ format)	Coffman et al., 2019	GSE118624

RESOURCE AVAILABILITY

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Lan Coffman (coffmanl@upmc.edu).

Materials Availability

All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Data and Code Availability

The DNA methylation EPIC array, ATAC-sequencing and ChIP-sequencing datasets generated in this study is available at NCBI without restriction. The accession number for the EPIC array is GSE138072, for the ATAC-seq data is SRP289005, and for the ChIP-seq data is SRP289183.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human cancer cell lines

Ovarian cancer cell lines CAOV3 and OVCAR3 were purchased through ATCC. OVSAHO and the primary patient cell line, PT412, were kind gifts from Dr. R. Buckanovich. All cells were grown in DMEM (Dulbecco's Modified Eagle Medium), 10% fetal bovine serum

(FBS), and 1% penicillin-streptomycin. Cells were incubated at 37°C in a humidified incubator equilibrated with 5% CO₂. All cell lines were tested and verified negative for mycoplasma (last test 9/2019).

Human primary cell lines

Cancer associated mesenchymal stem cells (CA-MSCs) were derived from surgical resection of human ovarian cancer involving the fallopian tube, ovary and/or omental metastatic deposits. Normal mesenchymal stem cells (MSCs) were derived from surgical samples (fallopian tube or omentum) of women undergoing surgery for benign indications or risk reduction surgery. Patient's samples were obtained in accordance with protocols approved by the University of Michigan's IRB (HUM0009149) and University of Pittsburgh's IRB (PRO17080326). CA-MSCs and MSCs were grown in MEBM (Mammary Epithelial cell Basal Medium) supplemented with: 1% B27, 20ng/ml epidermal growth factor (EGF), 1% penicillin-streptomycin, 20ug/ml gentamycin, 1 ng/ml hydrocortisone, 5ug/ml insulin, 100um beta-mercaptoethanol, 10ng/ml recombinant human basic-fibroblast growth factor (bFGF), and 10% fetal bovine serum (FBS). Cells were incubated at 37°C in a humidified incubator equilibrated with 5% CO₂.

Mice

All experimental procedures were performed in accordance with protocol approved by the Institutional Animal Care and Use Committee at University of Pittsburgh. Female NSG (NOD scid gamma) mice (6-8 week-old) were used. All mice were group housed and kept under 12h:12h L/D conditions. Food and water were available *ad libitum* to all mice 24 hour period.

METHOD DETAILS

Tissue harvesting

Patients samples were obtained in accordance with protocols approved by the University of Michigan's IRB (HUM0009149) and University of Pittsburgh's IRB (PRO17080326). Tissue was processed for DNA, RNA and protein isolation as previously described (Coffman et al., 2016b, 2019). MSCs were isolated as previously described (McLean et al., 2011). Briefly, CA-MSCs were derived from surgical resection of human ovarian cancer involving the FT, ovary and/or omental metastatic deposits. Normal FT and omental MSCs were derived from surgical samples of women undergoing surgery for benign indications or risk reduction surgery. Cells were plated in supplemented MEBM, MSCs were selected for plastic adherence and cell surface marker expression (CD105, CD90, CD73 positive; CD45, CD34, CD14, CD19 negative). Adipocyte, osteocyte, and chondrocyte differentiation capacity was verified (following guidelines presented by the ISCT on the minimal criteria for defining multipotent mesenchymal stem cells (Dominici et al., 2006)) (Figures S8C and S8D). To ensure lack of fibroblast contamination, cells were screened for fibroblast markers fibroblast surface protein (FSP) via flow cytometry and alpha smooth muscle actin via immunohistochemistry (Figures S8C and S8D). Any cell line with a population > 5% differing from above criteria were FACs purified. Fibroblast differentiation was performed as previously described by growing MSCs with connective tissue growth factor (100 ng/ml) and ascorbic acid (50 μg/ml) for 2 weeks (Coffman et al., 2019). MSCs were maintained in culture as previously described and used at passage 5 or below (McLean et al., 2011). All cell lines were tested and verified negative for mycoplasma (last test 9/2019).

DNA methylation array

DNA was isolated from CA-MSCs derived from omental metastasis in 6 patients with high grade serous ovarian cancer (HGSC), 1 patient with ovarian carcinosarcoma, 1 patient with high grade serous carcinoma involving the FT, and 3 patients with high grade serous carcinoma involving the ovary. Samples from 4 patients with omental with initial radiographic involvement of HGSC treated with neoadjuvant chemotherapy and pathologic complete response in the omentum, 5 benign patient FT samples, 1 set of bilateral FTs from a BRCA2 germline patient, 4 benign patient normal omental MSCs and 2 adipose MSCs purchased through ATCC were also included. All normal MSCs were derived from patients undergoing surgery for benign indications. "A" and "B" indicate samples from the same patient from 2 distinct anatomic locations. A list of all samples with anatomic and histologic information is provided in Table S1. All MSCs used for DNA methylation analysis were at passage 5 or below. DNA underwent bisulphite conversion followed by analysis on the Illumina MethylationEPIC Beadchip microarray through the Genomics core at the University of Michigan and Van Andel Research Institute.

Assay for Transposase Accessible Chromatin with sequencing (ATAC-seq)

Nuclei were isolated from 4 CA-MSCs derived from omental metastasis of patients with high grade serous ovarian cancer, 2 normal omental MSCs and 2 adipose MSCs purchased from ATCC. All MSCs used for ATACseq analysis were at passage 5 or below. ATAC-seq was performed through Active Motif.

Histone mass spectrometry

CA-MSCs and MSCs used for ATAC-seq were also used for mass spectrometry to measure the relative abundance of 80 histone modifications through Active Motif. Histones were extracted from frozen cell pellets and digested with trypsin. Samples were analyzed on a triple quadrupole (QdQ) mass spectrometer directly coupled with an UltiMate 3000 Dionex nan-liquid chromatography

system. Three separate mass spec runs for each sample. Each modified and unmodified form of the monitored amino acid residue was quantified as the percentage of the total pool of modifications with mean and standard deviation reported.

Quantitative real-time PCR

RNA was isolated with the RNeasy Mini Kit (QIAGEN, Hilden, Germany) and on-column DNase treatment (QIAGEN, Hilden, Germany). RNA concentration was determined with NanoDrop ND-1000 Spectrophotometer. cDNA was synthesized with the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, Grand Island, NY) as previously described [21]. SYBR green- based RT-PCR was performed using the 7900HT Sequence Detection System (Applied Biosystems, Foster City, California) and respective primers. The comparative Ct method was used for data analysis with *GAPDH* as the comparator gene.

Immunoblotting

Cell pellets were homogenized in RIPA buffer (Pierce, Rockford, IL) with complete protease inhibitor (Roche, Basel, Switzerland). Insoluble material was removed by centrifugation at 16,000 g at 4°C for 15 mins. Protein concentrations were determined using the Bradford Protein Assay Kit (Bio-Rad, Hercules, CA). Equal amounts of protein were separated on 4%–12% NuPAGE SDS gel (Invitrogen, Grand Island, NY) and transferred onto a PVDF membrane. Anti-H3K27me3, anti-H3K27me2, anti-H4K16ac, anti-H3K27ac, anti-H3K79me1, anti-H3, anti-H4, anti-WT1 and anti-EZH2 (1:1000 dilution, Active Motif), anti-PAX8 (1:1000, Abcam) and anti-B-actin (1:10,000 dilution, Sigma-Aldrich, St. Louis, MO) were used. Bands were visualized using the ECL Kit (Pierce, Rockford, IL).

Quantitative Methylation Specific PCR (qMSP)

Bisulfite Conversion and DNA Yield

Bisulfite conversion of extracted cellular or tissue DNA was performed using the DNA Methylation-Lightning Kit (Zymo Research) according to manufacturer's instructions and eluted into 40 μ l DNA Elution buffer (Zymo Research). Post-bisulfite treatment DNA yields were quantified by MethyLight assay for the methylation-independent bisulfite converted (BSC) consensus ALU sequence, as previously described (Weisenberger et al., 2005), using primer and probe sequences: forward primer, 5'- GGT TAG GTA TAG TGG TTT ATA TTT GTA ATT TTA GTA -3'; reverse primer, 5'- ATT AAC TAA ACT AAT CTT AAA CTC CTA ACC TCA -3', spanning a 98-bp locus, and 100nM probe, 5'- \56-FAM\ CCT ACC TTA ACC TCC C -3' with Minor Groove Binder (MGB; ThermoFisher Scientific). PCR was performed using 10X Master Mix to yield a final volume of 25 μ l and final working concentrations of 16.6mM (NH₄)₂SO₄, 67mM Tris pH 8.8, 6.7mM MgCl₂, 10mM β -mercaptoethanol, 200 μ M of each deoxynucleotide triphosphate (dNTP) and 0.04 U/ μ l of Platinum Taq polymerase (ThermoFisher Scientific). Cycling conditions were 95°C for 5 minutes, followed by 50 cycles of (95°C for 5 s, 60°C for 30 s and 72°C for 30 s). Standards for quantification were created by serial dilution of pre-quantified BSC human male DNA (Promega). Amplification reactions were performed in duplicate using 96 well-plates using a CFX96 Touch Real-time PCR Detection System (Bio-Rad).

Locus-specific methylation analysis

qMSP assays (Lo et al., 1999) were developed and analytically-validated for five select loci: *SASH1*, *c13orf45*, *ELN*, *GATA6*, and *MARVELD2*, for which primer sequences and assay specifications are detailed in Table S1. A standard curve was created using serial dilutions of BSC Epitect unmethylated control DNA (QIAGEN) mixed with BSC CpG-Methylated HeLa Genomic DNA (New England BioLabs) (Lo et al., 1999).

Data Analysis

MSP results were analyzed using the CFX Manager v3.1 (Bio-Rad) using regression to obtain the mean quantification cycle (Cq) for each respective sample. Percent methylation was calculated for each sample using the BSC-ALU and BSC Control DNA standard curves, according to the formula % methylation = (# locus copies methylated in sample) / (# ALU-calculated genomic copies in sample).

CA-MSC encapsulation

CA-MSCs were encapsulated into 3% alginate as previously described (Schmitt et al., 2015). Briefly, 3% w/v sodium alginate was dissolved in PBS, filtered for sterility with a 0.2 μ m filter. Cells were mixed with the alginate solution and added dropwise into a 5mM solution of calcium chloride to allow for gelation. Alginate beads were washed 2x with PBS prior to use in assays. Cell viability over time was verified by transection of the alginate capsule after 2 weeks incubation in standard culture media (DMEM, 10% FBS, 1% pen/strep) and re-isolation and growth of previously encapsulated CA-MSCs. Also, CA-MSCs lentivirally transduced with a secreted luciferase construct were encapsulated in alginate and the media was sampled for secreted luciferase overtime using the Ready-to-glow Secreted luciferase reporter system (Takara).

Sphere assays

CA-MSCs transduced with lentiviral mT construct were mixed with lentiviral labeled GFP tumor cells (CAOV3, OVSAHO, OVCAR3) (as previously described (Coffman et al., 2019)) in a 1:1 ratio in ultra-low attachment 6 well plates grown in serum free supplemented MEBM as previously described (Coffman et al., 2019). Alternatively, CA-MSCs were added to the top of a 0.4 μ m transwell system

and tumor cells seeded in the bottom to prevent direct contact. After 5 days, the number of GFP+ spheres were counted. Experiments were repeated independently 3 times per tumor cell type.

Migration/Invasion assays

8μm transwells were coated with growth factor reduced Matrigel and allowed to solidify. GFP-tumor cells (CAOV3, OVSAHO, OVCAR3) with or without mT-CA-MSCs were added to the top of the transwell. Supplemented DMEM was added to the bottom of the transwell and cell migration/invasion through the coated membrane was quantified after 24hrs via fluorescent microscopy. Alginate encapsulated CA-MSCs were added in place of control CA-MSCs to determine the impact of preventing CA-MSC:tumor cell direct interaction. Experiments were repeated independently 3 times per tumor cell type.

Adhesion assay

5x10⁴ MSCs or CA-MSCs were cultured overnight in 12 well-plate to form a mono-layer. 5x10⁴ fluorescently labeled tumor cells (OVSAHO, OVCAR3 or pt412) were then added. After 30 minutes, cells were washed twice with PBS and the attached tumor cells were counted using a fluorescence microscope and quantified as the number of adherent cells per low power field (10x). Experiments were repeated independently 3 times per tumor cell type.

Cancer stimulation, cancer cell:MSC co-culture

MSCs were grown in a 1:1 ratio with ovarian tumor cells allowing for direct interaction or with use of a transwell system(0.4μm) to separate the two cell types to allow only indirect co-culture as previously described (Coffman et al., 2019). Cells were grown in 1:1 mixture of CA-MSC media (supplemented MEBM) and tumor cell media (supplemented DMEM) for 5 days under hypoxic conditions (1% O₂). Cells were isolated via FACs separation with fluorochrome labeled MSCs or tumor cells or removed from their respective transwell chamber.

CA-MSC classifier

As previously described (Coffman et al., 2019), we created a regression model based on the expression of 6 genes which accurately distinguishes normal MSCs from CA-MSCs: Annexin A8-like protein 2 (ANXA8L2), Collagen Type XV Alpha 1 Chain (COL15A1), Cytokine Receptor Like Factor 1 (CRLF1), GATA Binding Protein 4 (GATA4), Iroquois Homeobox 2 (IRX2), and TGF-β2. Expression values are the delta CT values compared to GAPDH levels. The regression equation is:

$$\frac{1}{1 + \text{LOGIT}(\left(\frac{(B1 * \text{ANXA8L2}) + (B2 * \text{COL15A1}) + (B3 * \text{CRLF1}) + (B4 * \text{GATA4}) + (B5 * \text{IRX2}) + (B6 * \text{TGF}\beta)}{7.62691}\right))}; B1 = -0.00622, B2 = 0.175026, B3 = 0.886027, B4 = -0.34594, B5 = 0.416952, B6 = -0.00824$$

Ascites complex isolation and flow cytometric analysis

Cellular complexes were isolated from ovarian cancer patients' ascites as follows: Bulk ascites was obtained within 2 hours of patient paracentesis and large debris was removed via passage through a 1000μm pluriStrainer (pluriSelect). Red blood cells were lysed using ACK lysis buffer (ThermoFisher Scientific). Cells were treated with DNase I to a final concentration of 0.1mg/ml with 15min incubation. Cells then underwent serial centrifugation at 400 g for 5 mins and washing with 2% FBS in PBS with visual inspection of cells after each spin. Washing and centrifugation was continued until only cellular complexes, with minimal single cells, were visualized. Cell complexes were used for down-stream applications. For flow cytometric analysis, the isolated complexes were enzymatically dissociated into a single cell suspension with trypsin (0.25%, 5-10min incubation). Cells were then stained with anti-CD90, anti-CD73, anti-CD105 (Stem-cell Technology), and anti-EpCAM (Novus) antibodies for 20 minutes at RT. The percentage of CAMSC (CD90, 73, and 105+) and tumor cells (EpCAM+) were calculated on live cells gating.

Immunofluorescence staining

Cellular complexes were isolated from ovarian cancer patients' ascites as above and immobilized on slides using the cytospin centrifuge as previously described (Koh, 2013). Then, the cellular complexes were fixed using methanol for 10 minutes. Immunofluorescence conjugated antibodies (anti-CD90, anti-CD73, anti-CD105 (Stem-cell Technology), and anti-EpCAM (Novus)) were added after permeabilize the cellular complexes with 0.1% Triton 100X. The stained cellular complexes were examined using Nikon A1 confocal microscope.

Orthotopic ovarian cancer mouse model

5x10⁵ OVCAR3 cells were injected alone (n = 5) or with control CA-MSCs (5x10⁵ cells) (n = 5) or encapsulated CA-MSCs (5x10⁵ cells) (n = 5) into the ovarian bursa of NSG mice. Mouse weight and health were monitored over time and mice were sacrificed when the first group of mice met endpoint criteria of > 10% weight loss and necropsy was performed.

For experiments assessing the impact of EZH2i on metastasis, OVCAR3 and CA-MSCs were injected into the ovarian bursa as above (n = 10 mice per group in cisplatin treated arms, n = 5 mice in the control arm). Two mice per group contained OVCAR3 cells expressing luciferase. These mice underwent weekly IVIS imaging as previously described (Coffman et al., 2016b). On day 14, mice

were treated with cisplatin (0.5mg/kg every other day x 3 doses) or vehicle control. Mice in the dual treatment arm started treatment on day 15 with GSK126 150mg/kg 3x weekly ongoing or vehicle control. Mice were monitored daily and all mice were sacrificed when one group met endpoint criteria of 10% weight loss.

Tail vein injection model

5×10^5 OVCAR3 cells were injected into NSG mice ($n = 10$ per group). Mice in the EZH2 inhibition group were treated with 300mg/kg of GSK126 (selleckchem) 3 x weekly for 1 week prior to injection and then 150mg/kg 3 x weekly for 2 weeks immediately after injection. Mice in the control group underwent parallel treatment with vehicle control and were treated with 150mg/kg 3x weekly for 2 weeks starting 2 weeks after treatment. Mice were euthanized at 4 weeks post tumor cell injection and necropsy performed. Quantitative human specific PCR was performed on whole lung isolates as previously described (Alcoser et al., 2011).

Chromatin Immunoprecipitation

Normal and CA-MSC cells were fixed in buffer containing 1% formaldehyde, 50 mM HEPES-KOH pH 7.6, 100 mM NaCl, 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0) for 10 min at room temperature with shaking before being quenched with 125 mM glycine 5 min at room temperature. Cells were collected by scraping in cold PBS, washed 2X with cold PBS, flash frozen in liquid N₂, and stored at -80°C until use. Cells were lysed in LB1 (50 mM HEPES-KOH pH 7.6, 140 mM NaCl, 1 mM EDTA, 10% Glycerol, 0.5% NP-40, 0.25% Triton X-100, Protease inhibitor cocktail (Roche cOmplete Mini tablets, EDTA-free)) for 20 min with rotation at 4°C and cleared by centrifugation at $300 \times g$ for 5 min at 4°C . Supernatant with intact nuclei was set aside. Cell pellets were lysed again in 4x LB1 (LB1 with 2% NP-40 and 1% Triton X-100) for 20 min. Intact nuclei from this and the saved supernatant were collected by centrifugation at $1,700 \times g$ for 5 min at 4°C . Nuclei were resuspended and washed in LB2 (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 200 mM NaCl, protease cocktail inhibitor) for 10 min with rotation at 4°C . Nuclei were collected by centrifugation at $1,700 \times g$ for 5 min at 4°C and gently rinsed 2x with LB3 (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 0.01% NP-40, protease cocktail inhibitor) while avoiding disturbing pellet. Nuclei were resuspended in 1 mL LB3 and transferred to a 1 mL milliTUBE (Covaris). Chromatin was sheared to a range of 300-600 base-pair fragments using a Covaris E220 evolution Focused ultrasonicator with the following parameters: Peak power (140.0), Duty Factor (5.0), Cycles/Burst (200), Duration (600 s), Temperature (4°C). Sheared chromatin was quantified by Bradford Assay, and 450 mg of chromatin was brought to 500 mL in LB3 and then an additional 500 mL of ChIP Cocktail Mix (40 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM EDTA pH 8.0, 1% Triton X-100, 0.5% NP-40, Protease inhibitor cocktail) was added. Prepared chromatin was pre-cleared by incubation with 20 mL of pre-washed Dynabeads Protein G magnetic beads (Invitrogen #10004D) for 3 hours at 4°C with rotation. After bead removal, 10% input (100 ml) of pre-cleared chromatin was removed and set aside. Pre-cleared chromatin was immunoprecipitated with 5 mL of H3K27me3 antibody (Cell Signaling #9733) or H3K27ac antibody (Active Motif #39133) overnight at 4°C with constant rotation. Protein G magnetic beads (35 ml/IP) were blocked in buffer containing PBS, 0.5% BSA, and 20 mg Herring Sperm DNA (Sigma #D7290) with rotation at 4°C overnight. Blocked beads were washed 3X with PBS and 0.5% BSA, then 2X with WB1 (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 5 mM EDTA pH 8.0, 0.5% NP-40, 1% Triton X-100). Immuno-chromatin complexes were incubated with blocked beads for 3 hours with rotation at 4°C . Beads were then washed 3X for 5 min with rotation at 4°C with WB1, 3X with WB2 (50 mM Tris-HCl pH 7.6, 500 mM NaCl, 5 mM EDTA pH 8.0, 0.5% NP-40, 1% Triton X-100), 2X with WB1, and 1X with Low Salt TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 50 mM NaCl). Beads were incubated in 50 mL of Elution Buffer (10 mM Tris-HCl pH 8.0, 10 mM EDTA, 150 mM NaCl, 5 mM DTT, 1% SDS) at 65°C for 15 min in 50 mL volume. The elution step was repeated, and eluates combined. Eluates and input were incubated overnight at 65°C with constant shaking to reverse crosslinks, followed by incubation at 37°C for 1 hour with DNase-free RNase A, then incubation at 37°C for 2 hours with 10 mL of Proteinase K (20 mg/ml stock). DNA was isolated with a 1.5x ratio of KAPA Pure Beads (KAPA Biosystems #KK8000) to DNA volume. After quantification with a Qubit dsDNA High Sensitivity Assay kit (ThermoFisher Scientific #Q32851), library preparation was done using a KAPA HyperPrep Kit (Kappa Biosystems #07962347001).

Transcriptome data re-processing

Raw mRNA sequencing data (FASTQ format) of 4 normal omental MSCs and 10 ovarian CA-MSCs, using Illumina TruSeq RNA Sample Preparation V2 kit (Illumina San Diego, CA, USA) and Illumina HiSeq2000 instrument 100 bp PE sequencing, were downloaded through NCBI's Gene Expression Omnibus (GEO) with GEO Series accession number GSE118624 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118624>) (Coffman et al., 2019). Each raw sequencing file was aligned to the human reference genome (GRCh37) using STAR version 2.7 (Dobin et al., 2013), with default settings. Estimation of gene-level abundance was carried out using RSEM version 1.3.1 (Li and Dewey, 2011). Raw reads count from RSEM were further normalized using R package *edgeR* (function cpm), and log-transformed for downstream analysis, with one CA-MSC sample (GSM3335697) removed due to potential tumor cell contamination.

DNA methylation data processing and QC

Raw IDATs files were processed using R package SeSAMe (Zhou et al., 2018) with noob background correction, non-linear dye bias correction, and non-detection masking (any data point not significantly different from background was replaced with NA). Probes with design issues (Zhou et al., 2017) were also masked. DNA methylation beta values, ranging from 0 to 1 (with "0" indicating fully unmethylated and "1" fully methylated), were calculated as quantitative percentage of methylated signals over both methylated and

unmethylated signals. All IDATs and processed beta values have been uploaded and made available through Gene Expression Omnibus (GEO) under the accession number GSE138072.

SNP probes ('rs' probes) were used to examine potential sample swaps which can occur in genomic studies. No such swap was identified. DNA Methylation beta values for three MIR141/200C promoter probes ("cg12161331," "cg18185189," "cg19794481") were examined to track mesenchymal content within each sample. MIR141/200C is considered to be a master regulator for epithelial/mesenchymal phenotype transition, and this process is controlled by its promoter methylation state (Vrba et al., 2010). Methylation level at these three probes used highly correlated with mesenchymal content in flow sorting results (George et al., 2019). Two samples had a failure rate of > 40% with our stringent background masking (Zhou et al., 2018) likely due to DNA degradation, but were kept in the study, using data points that passed the stringent filter.

ATAC sequencing (ATAC-seq) data processing

Quality control was carried out using the PEPATAC pipeline adopted by the TCGA ATAC-seq project (Corces et al., 2018). We followed current ENCODE QC standards and excluded four samples due to insufficient transcription start site (TSS) enrichment value (less than 6), therefore were removed from further analysis. Next, raw sequencing reads were mapped to the human reference genome (GRCh37) using Burrows-Wheeler Alignment tool (BWA) with default settings (Li and Durbin, 2009), followed by peak calling with software MACS2 (Zhang et al., 2008). Specifically, parameters of `-nomodel` and `-f BAMPE` were specified in calling open chromatin regions, for pileup of the whole fragments. Sample-based open peaks were then merged across all the samples, and fed into R package DESeq2 (Love et al., 2014) to generate a normalized reads count matrix against effective library sizes.

ChIP sequencing (ChIP-seq) data processing

Raw sequencing reads for histone marks H3K27me3 and H3K27ac were mapped to the human reference genome (GRCh37) using Burrows-Wheeler Alignment tool (BWA) with default settings (Li and Durbin, 2009). Reads for samples with multiple runs were merged ahead of mapping. Normalized signal within 10 bp bins across the genome was calculated using deeptools2 (Ramírez et al., 2016), with parameters "`--normalizeUsing RPGC`." RPGC (per bin) equals the number of reads per bin divides by scaling factor for 1x average coverage. A scaling factor was computed with R package `csaw` (Lun and Smyth, 2016), to generate effective library size. Peak calling procedure was carried out using MACS2 (Zhang et al., 2008) with default settings.

Public available data resources

DNA methylation data (Illumina HM450 array) of ovarian stroma samples (N = 4 from the TCGA UCEC project; these samples were annotated as 'normal ovary' and pathologist evaluation of available slides confirms ovarian stroma histology) were downloaded from the Genomic Data Commons (GDC) Data Portal (<https://portal.gdc.cancer.gov>), together with that of Uterine Carcinosarcoma (UCS; N = 57) and Sarcoma (SARC; N = 261). Pure, uncultured fallopian tube epithelium samples (FTE; N = 4) were downloaded through GEO database, with one sample GSM2146822 taken from Series GSE81224 (Klinkebiel et al., 2016), and the other three samples (GSM1606969, GSM1606970, and GSM1606973) from Series GSE65820 (Patch et al., 2015). Other FTE samples in the same studies either had insufficient epithelial purity or had undergone *in vitro* culturing and therefore not included. All DNA methylation microarray data were reprocessed from raw IDATs in the same way as described above for the MSCs. Gapped H3K27me3 chromatin peak files of MSC-derived from adipose, bone marrow, chondrocyte, and H1 stem cell were downloaded through the NIH Roadmap Epigenomics projects (<http://www.roadmapepigenomics.org/data/>). EZH2 target genes were then defined as genes overlapping with H3K27me3 marked regions shared by all four different cell types.

QUANTIFICATION AND STATISTICAL ANALYSIS

Data are presented as mean \pm SEM unless otherwise stated. Details are found in the Results section and figure legends. All experiments were performed on at least three patient derived CA-MSCs. Student's unpaired t test or ANOVA were used to determine the statistical significance. Differences were considered significant at $p < 0.05$.

Identification of differential genes

Differential gene expression analysis was carried out using R package Limma (Ritchie et al., 2015). Specifically, differentially expressed genes were identified based on a p value less than 0.05, and an absolute log-transformed fold change greater than 1.5. Followed by functional enrichment analysis using R package clusterProfiler (Yu et al., 2012), with FDR cutoff at 0.05 for KEGG pathway, Gene Ontology (Biological Process), and Gene Set Enrichment Analysis (GSEA). In particular for GSEA, genes were ranked based on log-transformed fold changes by comparing sample group of CA-MSC to MSC.

Unsupervised DNA methylation analysis

Unsupervised hierarchical clustering was performed on top variable CpG probes (N = 10,000, filtered by standard deviations) across all CA-MSC and MSC samples measured on the EPIC array with the R function `hclust()`. Uniform Manifold Approximation and Projection (UMAP) was performed with the R package `uwot`.

Identification of CA-MSC/FTE/MS-specific probe sets

For global comparison of CAMSC/FTE/MSCs, different probe categories are defined as such: 1) CA-MSC and FTE shared hyper-methylated probes: mean methylation difference > 0.4 in both CA-MSC to MSC, and FTE to MSC comparisons; 2) CA-MSC-specific hyper-methylated probes: mean methylation difference > 0.4 when comparing CA-MSC to MSC, but absolute mean methylation difference < 0.1 when comparing FTE to MSC; 3) FTE-specific hyper-methylated probes: mean methylation difference > 0.4 when comparing FTE to MSC, but absolute methylation difference < 0.1 when comparing CA-MSC to MSC; 4) CA-MSC and FTE shared hypo-methylated probes: mean methylation difference < -0.4 in both CA-MSC to MSC, and FTE to MSC comparisons; 5) CA-MSC-specific hypo-methylated probes: mean methylation difference < -0.4 when comparing CA-MSC to MSC, but absolute methylation difference < 0.1 when comparing FTE to MSC; 6) FTE-specific hypo-methylated probes: mean methylation difference < -0.4 when comparing FTE to MSC, and absolute mean methylation difference < 0.1 when comparing CA-MSC to MSC.

Identification of differential DNA methylation and functional enrichment analysis

Differentially methylated cytosines (DMCs) were calculated using R package DMRcate (Peters et al., 2015), by comparing sample group of CA-MSC to MSC, based on its default FDR cutoff of 0.05. We removed probes with any missing value (NA) in any of the samples, leaving a total of $\sim 401,000$ probes for any analyses involving DMR/DMC calling. DMCs were split into hypermethylated (hyper-) and hypomethylated (hypo-) DMCs, by comparing group of CA-MSC to MSC. Enrichment or depletion of various genomic features (annotated with R package *annotatr* for each probe) in hyper- and hypo DMCs were measured as odds ratios, together with significance level calculated using Chi-square test. And the probe set for DMR/DMC calling was used as the background for the enrichment or depletion analysis.

Transcription factor binding site enrichment analysis

DMCs were mapped to genes captured by mRNA sequencing, if they were located within gene promoter regions defined as ± 1.5 kb away from transcription start sites (TSSs). Annotation of CpG probes against transcription factor binding sites (TFBSs) were adopted from our previous study (Zhou et al., 2017). We then performed enrichment analysis of TFBSs over differentially methylated probes at distal regulatory elements (i.e., potential enhancers). Distal probes were defined as probes located within TFBSs, but not overlapping with ± 2 kb flanking regions surrounding TSSs. For each set of hyper- or hypo-DMCs, hypergeometric test was applied to calculate the enrichment of binding sites for each TF within the set of DMCs within all distal probes. Significance cutoff was made at $p = 1e-3$ after false discovery rate (FDR) correction.

Identification of differential ATAC-seq peaks, functional enrichment, and PCA analysis

Log-transformed reads count were used for further differential peak analysis, with reads counts of replicates from the same sample averaged. Enrichment or depletion of differential ATAC-seq peaks against various genomic features was carried out in a similar way as in differential methylation analysis. Peaks merged from all the samples were served as the background. Principal component analysis (PCA) was performed, based on the normalized reads count matrix. Peak summit centered heatmap per sample was generated with deepTools using normalized 10 base pair bin-based ATACseq signal (Ramírez et al., 2016).

Key Resources Table references

(Corces et al., 2018; Li, 2013; Zhang et al., 2008; Ripley, 2001; Dobin et al., 2013; Li and Dewey, 2011; Ramírez et al., 2016; Subramanian et al., 2005; Karolchik et al., 2003; Zhou et al., 2017; Yue, 2018; Coffman et al., 2019)

Cell Reports, Volume 33

Supplemental Information

Epigenomic Reprogramming toward Mesenchymal- Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis

Huihui Fan, Huda I. Atiya, Yeh Wang, Thomas R. Pisanic, Tza-Huei Wang, Ie-Ming Shih, Kelly K. Foy, Leonard Frisbie, Ronald J. Buckanovich, Alison A. Chomiak, Rochelle L. Tiedemann, Scott B. Rothbart, Chelsea Chandler, Hui Shen, and Lan G. Coffman







Figure S1. Additional DNA methylation differences in CA-MSCs vs MSCs, Related to Figure 1.

- A. DNA methylation heatmap of top differentially methylated loci (FDR<0.05, and absolute group beta value difference > 0.4) between tumor samples and CA-MSCs. Probes are plotted as rows, with samples plotted as columns. Sample group of tumor, normal MSC, and CA-MSC is plotted as column annotation, together with sample isolation source if samples are normal MSCs or CA-MSCs. A blue-to-red gradient indicates a beta value of 0-1 (DNA methylation level of 0% to 100%). Sample CA-MSC_OM10 with heavy epithelial contamination is highlighted. Isolation site abbreviations: FT, fallopian tube; AD, adipose; OM, omentum; OV, ovary; OMMets, metastasis from omentum.
- B,C. Enrichment of CA-MSC hyper-methylated loci (B) and hypo-methylated loci (C) against different genomic features of CpG and genic annotations. CpG annotations include open sea (cpg_inter), CpG shores (cpg_shores), CpG shelves (cpg_shelves), CpG islands (cpg_islands). Genic annotations contain 1-5Kb upstream of the TSS (genes_1to5kb), the promoter (< 1Kb upstream of the TSS; genes_promoters), 5'UTR (genes_5UTRs), first exons (genes_firstexons), exons (genes_exons), introns (genes_introns), CDS (genes_cds), 3'UTR (genes_3UTRs), and intergenic regions (the intergenic regions exclude the previous list of annotations; genes_intergenic). Odds ratio and 95% confidence interval (CI) for each feature are shown. Significance level is labeled in parentheses.
- D. Scatter plots showing DNA methylation beta values in CA-MSC (shared y axis) versus fallopian tube epithelium (FTE) samples (x axes), stratified by the methylation level in normal MSCs. Each dot represent one CpG, as measured by one DNA methylation probe. Linear regression lines are plotted in blue, with corresponding regression coefficient (aka. slope) indicated on top of each panel.





Figure S2. DNA methylation changes persists with MSC differentiation, Related to Figure 2.

A,B. DNA methylation levels at the five-locus panel for MSCs (A) and CA-MSCs (B) with adipose ('adi') and fibroblast ('fibro') lineage differentiation. Y axis indicates % methylation as determined by MSP. Ttest between MSCs at each loci $p > 0.05$. Mean & SEM of 3 independent samples are represented.








Figure S3. Additional ATAC-seq, pathway analysis and cellular abundance of CA-MSCs vs MSCs, Related to Figure 3 and 4.

- A,B. Enrichment of CA-MSC closed (A) and open (B) ATAC-seq peaks against different genomic features of CpG and genic annotations defined as in Supp Figure S1B,C. Odds ratio and 95% confidence interval (CI) for each feature are shown. Significance level is labeled in parentheses.
- C. Gene ontology (GO) enrichment analysis (biological concept of Biological Process; GOBP). The numbers of up- and down-regulated genes comparing CA-MSCs to MSCs are labeled underneath the plot. Each dot represents a GOBP term, with dot size indicating enrichment score (ES), and dot color representing significance level. Two cell adhesion related processes are highlighted for genes upregulated in CA-MSCs.
- D. KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis. Two pathways relevant to cell adhesion are highlighted for upregulated genes, and two pathways relevant to EMT (epithelial-mesenchymal transition), the reverse process of MET, are highlighted for downregulated genes.
- E. MSC quantification from benign and HGSC involved human tissues and ascites. MSCs quantified via flow cytometry (CD90, 73, 105+/CD45, 34, 14, 19- population) and represented as percentage of total viable cell population.






Figure S4. CA-MSCs have altered collagen secretion associated with increased metastasis, Related to Figure 3.

- A. qRT-PCR of *COL15* and *COL4* expression in normal MSCs and CA-MSCs. Fold change compared to normal MSC is expressed. Results are the mean and SEM of 3 independent cell lines.
- B. Immunofluorescence of COL4 (red) and COL15 (green) during adherent CA-MSC and normal MSC culture demonstrating increased CA-MSC secretion of COL4 and decreased secretion of COL15. Scale bar=10microns.
- C. Immunofluorescence of COL4 and COL15 in benign omentum and omental HGSC metastasis demonstrating increased COL4 and decreased COL15 in omental metastasis. Scale bar=20microns




Figure S5. Additional tumor cell adhesion and CA-MSC verification, Related to Figure 4.

- A. OVCAR3 binding to plastic, normal omentum (OM) MSCs, CA-MSCs derived from the OM and ovary (OV) demonstrates increased tumor cell adhesion to CA-MSCs. Results quantified by counting fluorescent tumor cells per high power field (HPF). Mean & SEM of 3 independent experiments is represented.
- B. Immunohistochemistry of cytospin of CA-MSC:tumor cell complexes isolated from patient ascites demonstrating strong PAX8 expression in tumor cells and not CA-MSCs. Scale bar=20microns
- C. PAX8 western blot of ovarian tumor cells and CA-MSCs isolated from ascites, omental metastasis and normal MSCs demonstrating CA-MSCs have minimal PAX8 expression which is similar to normal MSC levels and less than tumor cell levels.
- D. CA-MSCs isolated from tissue and ascites complexes were verified to meet MSC differentiation and surface expression criteria. Representative flow cytometry plots characterizing MSCs based on CD105,73,90 positivity and CD34,45,11b negativity and negativity for the fibroblast marker, fibroblast surface protein (FSP). Last plot demonstrates the population triple positive for CD105, 73 and 90. Y axis represent side scatter unless otherwise noted.
- E. Immunohistochemistry of undifferentiated and differentiated MSCs (adipocyte: oil red o; osteocyte: alizarin red; chondrocyte: alcian blue). Immunofluorescence of alpha-smooth muscle actin (α SMA) in undifferentiated and fibroblast differentiated MSCs demonstrating staining only after fibroblast directed differentiation.
- F. Ratio of tumor cells to CA-MSCs in cellular complexes isolated from ascites. N=4 independent patients.
- G. Secreted luciferase levels (OD measurement) in control media versus media from luciferase-secreting CA-MSCs in standard culture or alginate encapsulated CA-MSCs. Mean and SEM of 3 independent experiments.






Figure S6. The 3D Genome Browser view in combination with the UCSC genomic view for gene *WT1* locus, Related to Figure 5.

A. Circular chromosomal conformation capture (4C) data in cell line K562 is plotted as a curve line (resolution is 5kb), where the center is the bait region (*WT1* TSS, covered by green box, Region 1) and a peak signal indicates there is a chromatin interaction event between the TSS and a potential distal regulatory region supported by HiC reads covering both regions (y-axis).

B-F. (B) DNase I-hypersensitive sites (DHS) linkage track and (C) UCSC tracks of HiC heatmap in K562, (D) gene track, (E) H3K27ac histone marks, and (F) enhancer, promoter, and regulatory interactions curated in GeneHancer database. Intense DHS interactions between the *WT1* promoter region (green box, Region 1) and the first potential enhancer within its gene body (cyan box, Region2) also supports the potential interactions. Dashed green lines and circle show consistency between the UCSC HiC heatmap track (resolution is 5kb) and the peak covered by cyan box (Region 2) from the 4C curve view. Orange box (Region 3) marks a second enhancer within gene *WT1*, which overlaps with known enhancer annotation, and interaction with the *WT1* promoter curated in the GeneHancer database.




A**ROADMAP MSC H3K27me3 Histone Marks****B****C**

Figure S7. H3K27me3 peak overlap and verification of histone mass spectrometry, Related to Figure 6.

- A. Venn diagram showing H3K27me3 peak overlaps among MSCs derived from different sources of adipose, chondrocytes, bone marrow, and H1 cell line. The common set of 1,241 narrow peak regions (as in red) is defined as the EZH2 targets, if they are located within their transcriptional regions plus 2 kb upstream flanking regions of their TSSs.
- B. Western blot verification of differential histone modifications identified by mass spectrometry.
- C. Densitometry quantification of western blot analysis of histone modifications normalized to actin (for H4K16ac and H1K26me1) and H3 (for H3 modifications), in 5 CA-MSCs compared to 3 MSCs. T- test p values between CA-MSC and normal MSC are labeled on top of the bar set for each histone type.





A**B****C****D**

Figure S8. EZH2 inhibition does not impact tumor cell viability and additional EZH2 inhibitors similarly decrease CA-MSC formation, Related to Figure 4, 6 and STAR methods tissue harvesting.

- A. Viability of tumor cells PT412 and OVCAR3 and normal MSCs after 5 days treatment with 20nM GSK126 compared to vehicle control.
- B. Quantification of the percent of conversion to CA-MSC in WT1 KD MSCs or scrambled control after cancer stimulation (CS) with hypoxic direct cancer cell co-culture with and without a different EZH2 inhibitor, Tazemetostat. Values are normalized to scrambled control conversion based on CA-MSC classifier score. *, ** = comparison to treatment group scrambled control; \$ = comparison to CS scrambled control without Tazemetostat. Mean & SEM of 3 independent experiments are shown.
- C. EZH2 inhibition limits metastasis formation. Percentage of metastasis formation (y-axis) at different organ sites (x-axis) is shown between EZH2 inhibition and control group in a tail vein injection metastasis model.
- D. Pulmonary tumor burden is shown between EZH2 inhibition and control group.

Table S1

SampleName	SampleID	PatientID	SampleGroup	SampleEPIC	Source	SourceCode
CAMSC_OM01	493_camsc	s493	CAMSC	201557520003_R03C01	CA-MSCs derived from the omental metastasis of patients with high grade serous ovarian cancer	CAMSC-OMmets
CAMSC_OM02	549_camsc	s549	CAMSC	201557520040_R03C01	CA-MSCs derived from the omental metastasis of patients with high grade serous ovarian cancer	CAMSC-OMmets
CAMSC_OM03a	CAMSC1	s0009	CAMSC	200516380137_R01C01	CA-MSCs derived from the omental metastasis of patients with high grade serous ovarian cancer	CAMSC-OMmets
CAMSC_OM03b	CAMSC2	s0009	CAMSC	200516380137_R02C01	CA-MSCs derived from the omental metastasis of patients with high grade serous ovarian cancer	CAMSC-OMmets
CAMSC_OM05	CAMSC3	s0003	CAMSC	200516380137_R03C01	CA-MSCs derived from the omental metastasis of patients with high grade serous ovarian cancer	CAMSC-OMmets
CAMSC_OM06a	CAMSC6	s0006	CAMSC	200516380137_R06C01	CA-MSCs derived from the omental metastasis of patients with high grade serous ovarian cancer	CAMSC-OMmets
CAMSC_OM06b	CAMSC7	s0006	CAMSC	200516380137_R07C01	CA-MSCs derived from the omental metastasis of patients with high grade serous ovarian cancer	CAMSC-OMmets
CAMSC_OM08	CAMSC8	s0008	CAMSC	200516380137_R08C01	CA-MSCs derived from the omental metastasis of patients with ovarian carcinosarcoma	CAMSC-OMmets
CAMSC_OM09	CAMSC9	s0009	CAMSC	200526210119_R01C01	CA-MSCs derived from the omental metastasis of patients with high grade serous ovarian cancer	CAMSC-OMmets
CAMSC_OM10	406_camsc	s406	CAMSC	201557520040_R02C01	CA-MSCs derived from the omental metastasis of patients with high grade serous ovarian cancer	CAMSC-OMmets
CAMSC_FT01	19-175 FT.camsc	s19-175	CAMSC	203020780110_R04C01	CAMSCs derived from fallopian tube involved with high grade serous ovarian cancer	CAMSC-FT
CAMSC_OV01	19-90 ov.camsc	s19-90	CAMSC	203020780110_R05C01	CAMSCs derived from ovary involved with high grade serous ovarian cancer	CAMSC-OV
CAMSC_OV02	19-95 ov.camsc	s19-95	CAMSC	203020780110_R06C01	CAMSCs derived from ovary involved with high grade serous ovarian cancer	CAMSC-OV
CAMSC_OV03	19-263 ov.camsc	s19-263	CAMSC	203038250154_R06C01	CAMSCs derived from ovary involved with ovarian cancer	CAMSC-OV
MSC_OMneo01	18-0030 neo n.om	s18-0030	MSC	203020780110_R08C01	MSCs derived from omentum that was initially involved with high grade serous ovarian cancer but had a complete pathologic response to neoadjuvant chemotherapy	MSC-OMneo
MSC_OMneo02	18-0054 neo n.om	s18-0054	MSC	203013220061_R01C01	MSCs derived from omentum that was initially involved with high grade serous ovarian cancer but had a complete pathologic response to neoadjuvant chemotherapy	MSC-OMneo
MSC_OMneo03	18-0048 neo n.om	s18-0048	MSC	203013220061_R02C01	MSCs derived from omentum that was initially involved with high grade serous ovarian cancer but had a complete pathologic response to neoadjuvant chemotherapy	MSC-OMneo
MSC_OMneo04	19-107 n.om (neo)	s19-107	MSC	203013220061_R03C01	MSCs derived from omentum that was never involved with cancer (stage II ovarian cancer) but patient had neoadjuvant chemotherapy	MSC-OMneo
MSC_FT01	19-120 n.FT	s19-120	MSC	203013220061_R04C01	MSCs derived from normal fallopian tube	MSC-FT
MSC_FT02	19-197 n.FT	s19-197	MSC	203013220061_R05C01	MSCs derived from normal fallopian tube	MSC-FT
MSC_FT03	19-128 n.FT	s19-128	MSC	203013220061_R06C01	MSCs derived from normal fallopian tube but with hydrosalpinx	MSC-FT
MSC_FT04	AL n.FT	s0007	MSC	203013220061_R07C01	MSCs derived from normal fallopian tube	MSC-FT
MSC-FT-Brcal	19-257 LFT BRCA2	s19-257	MSC	203038250154_R02C01	MSCs derived from left fallopian tube with BRCA2 mutation	MSC-FT
MSC-FT-Brcar	19-257 RFT BRCA2	s19-257	MSC	203038250154_R03C01	MSCs derived from right fallopian tube with BRCA2 mutation	MSC-FT
MSC_FT07	19-223 #2 nFT	s19-223	MSC	203038250154_R04C01	MSCs derived from normal fallopian tube	MSC-FT
MSC_ADD01	amsc_1125	s1125	MSC	201557520040_R04C01	MSCs derived from adipose purchased through ATCC	MSC-AD
MSC_ADD02	amsc_2118	s2118	MSC	201557520003_R05C01	MSCs derived from adipose purchased through ATCC	MSC-AD
MSC_OM01a	MSC1	s0001	MSC	200526210119_R02C01	MSCs derived from normal omental tissue undergoing surgery for benign indications	MSC-OM
MSC_OM01b	MSC2	s0001	MSC	200526210119_R03C01	MSCs derived from normal omental tissue undergoing surgery for benign indications	MSC-OM
MSC_OM01c	MSC5	s0001	MSC	200526210119_R06C01	MSCs derived from normal omental tissue undergoing surgery for benign indications	MSC-OM
MSC_OM01d	MSC6	s0001	MSC	200526210119_R07C01	MSCs derived from normal omental tissue undergoing surgery for benign indications	MSC-OM
MSC_OM05	18-691 n.om CC	s18-691	MSC	203013220061_R08C01	MSCs derived from normal omentum from patient with a stage II clear cell endometrial cancer	MSC-OM
MSC_OM05b	18-691 n.om CC	s18-691	MSC	203038250154_R01C01	MSCs derived from normal omentum from patient with a stage II clear cell endometrial cancer	MSC-OM
MSC_OM07	19-319 n.om	s19-319	MSC	203038250154_R05C01	MSCs derived from normal omentum	MSC-OM

Table S1. Sample list summary, Related to Figure 1 and STAR methods DNA methylation array